



Induction of PI3K/Akt-Mediated Apoptosis in Osteoclasts Is a Key Approach for *Buxue Tongluo* Pills to Treat Osteonecrosis of the Femoral Head

OPEN ACCESS

Edited by:

Hong Zhang, Shanghai University of Traditional Chinese Medicine, China

Reviewed by:

Xiaofei Zhang, Shaanxi University of Chinese Medicine, China Lei Chen, Guangdong Pharmaceutical University, China

*Correspondence:

Qiang Ren 401627406@qq.com Xiaoping Tian tianxiaoping@cdutcm.edu.cn Yunhui Chen chenyunhui@cdutcm.edu.cn [†]These authors have contributed equally to this work and share first authorship

Specialty section:

This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

Received: 24 June 2021 Accepted: 04 October 2021 Published: 29 November 2021

Citation:

Wang D, Liu Y, Tang D, Wei S, Sun J, Ruan L, He L, Li R, Ren Q, Tian X and Chen Y (2021) Induction of PI3K/Akt-Mediated Apoptosis in Osteoclasts Is a Key Approach for Buxue Tongluo Pills to Treat Osteonecrosis of the Femoral Head. Front. Pharmacol. 12:729909. doi: 10.3389/fphar.2021.729909 ¹School of Pharmacy, School of Basic Medicine, Innovative Institute of Chinese Medicine and Pharmacy, School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China, ²Neijiang Hospital of Traditional Chinese Medicine Affiliated to Chengdu University of Traditional Chinese Medicine, Neijiang, China, ³Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

Dan Wang^{1†}, Yicheng Liu^{2†}, Dandan Tang¹, Shujun Wei¹, Jiayi Sun¹, Lvqiang Ruan², Lin He¹,

Ruolan Li¹, Qiang Ren³*, Xiaoping Tian¹* and Yunhui Chen¹*

The Buxue Tongluo pill (BTP) is a self-made pill with the functions of nourishing blood, promoting blood circulation, dredging collaterals, and relieving pain. It consists of Angelica sinensis (Oliv.) Diels, Pheretima aspergillum (E.Perrier), Panax notoginseng (Burk.) F. H. Chen, Astragalus membranaceus (Fisch.) Bge, and Glycyrrhiza uralensis Fisch. Various clinical practices have confirmed the therapeutic effect of BTP on osteonecrosis of the femoral head (ONFH), but little attention has been paid to the study of its bioactive ingredients and related mechanisms of action. In this study, UPLC/MS-MS combined with GEO data mining was used to construct a bioactive ingredient library of BTP and a differentially expressed gene (DEG) library for ONFH. Subsequently, Cytoscape (3.7.2) software was used to analyze the protein-protein interaction between BTP and DEGs of ONFH to screen the key targets, and functional annotation analysis and pathway enrichment analysis were carried out. Finally, 34 bioactive compounds were screened, which acted on 1,232 targets. A total of 178 DEGs were collected, and 17 key genes were obtained after two screenings. By bioinformatics annotation on these key genes, a total of 354 gene ontology (GO) functional annotation analyses and 42 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were obtained. The present study found that GO and KEGG enrichment were mainly related to apoptosis, suggesting that BTP may exert an anti-ONFH effect by promoting osteoclast apoptosis. Experiments in vitro demonstrated that BTP could increase the mitochondrial membrane potential (MMP) and induce remarkable apoptosis in osteoclasts. Furthermore, we determined the apoptosis marker of cleaved(C)-caspase-3, bcl-2, and bax and found that BTP could upregulate the C-caspase-3 and bax expression in osteoclasts and decrease the expression of bcl-2, p-Akt, and p-PI3K in a dose-dependent manner, indicating that BTP could induce PI3K/Akt-mediated apoptosis in osteoclasts to treat ONFH. This study explored the pharmacodynamic basis and mechanism of BTP against ONFH from the perspective of systemic pharmacology, laying a foundation for further elucidating the therapeutic effects of BTP against ONFH.

Keywords: buxue tongluo pill, osteonecrosis of the femoral head, GEO database, apoptosis, PI3K/AKT

INTRODUCTION

Osteonecrosis of the femoral head (ONFH) refers to a disease in which the blood supply of the femoral head is damaged or interrupted, leading to the death of bone marrow components and bone cells and the structural change and collapse of the femoral head (Pouya and Kerachian, 2015). It has also been considered a debilitating disease of multifactorial genesis, predominately affecting young people aged 20-40 years with the destruction of hip joints in their third, fourth, or fifth decade of life (Sun and Li, 2013). Currently, approximately 20,000-30,000 patients in the United States are diagnosed with ONFH annually, bringing pain and a substantial economic burden to the patients. Treatment options available for ONFH include pharmaceutical intervention and surgical treatment. Unfortunately, the former often fails to achieve satisfactory results due to the rapid progress of ONFH, and concerns regarding the longevity of the hip replacement have always existed. Thus, ONFH has been widely regarded as a global problem (Ping, 2021). Recently, traditional Chinese medicine (TCM) has been gradually accepted as a complementary and alternative medicine for the treatment of multiple diseases due to low toxicity and good curative effects (Xu et al., 2021; Zhang et al., 2021). A growing amount of TCM compounds and monomers, such as Bushen Huoxue decoction (Sun and Li, 2013), Huangqi Shenggu decoction (Ping, 2021), Taohong Siwu decoction (Zhao, 2020), Gastrodin (Zheng et al., 2014), and luteolin (Yan et al., 2020), have been reported to exert a significant therapeutic effect on ONFH.

BTP is a TCM formula that has been proven effective in treating ONFH with the functions of "promoting blood supply". It is composed of Angelica sinensis (Oliv.) Diels, Pheretima aspergillum (E.Perrier), Panax notoginseng (Burk.) F. H. Chen, Astragalus membranaceus (Fisch.) Bge, and Glycyrrhiza uralensis Fisch. Although it is frequently used to treat ONFH in clinical practice, there is no research for the specific mechanism regarding the anti-ONFH effect of BTP. Moreover, the TCM formula is characteristic of multicomponents, multitargets, and multipathways, making it difficult to reveal their mechanisms of action (Xu et al., 2021). Network pharmacology is a technology that can systematically analyze the interaction network of drug components, targets, diseases, and genes, which is consistent with the overall concept of the TCM theoretical system (Hopkins, 2008). At present, increasing studies have confirmed the great potential of network pharmacology in investigating the possible molecular mechanisms of TCM (Shan et al., 2018; Cui et al., 2018; Daina et al., 2019; Wang et al., 2020; Xia et al., 2021). Thus, it is an inevitable trend to apply network pharmacology to investigate the material basis and molecular mechanism of the TCM formula (Qing and Jia, 2021; Qing and Hu, 2021; Qing and Jia, 2019). In the current study, UPLC-MS/ MS was used to identify the active ingredients of BTP, and network pharmacology was used to study the molecular mechanisms of BTP against ONFH. Besides,

experiments *in vitro* were performed to provide scientific evidence for the predicted results with the network pharmacology. The general experimental procedures are shown in **Figure 1**.

METHODS

Preparation of the Extracts of BTP

BTP samples were prepared and provided by Neijiang traditional Chinese medicine hospital (Neijiang, China). The powder of BTP (10 g) was ultrasonically dissolved with 300 ml, 75% ethanol, followed by concentrating to 100 ml using a rotary evaporator. Then, the supernatant was filtered by microporous membranes with a pore size of 0.22 μ m. Then, the obtained 10 μ l filtrates of BTP were analyzed by UPLC-MS/MS.

UPLC-MS/MS Analysis

For qualitative analysis, a Thermo Scientific Q Exactive Orbitrap HRMS (Thermo Fisher Scientific, Massachusetts, United States) was connected to a Thermo Scientific Vanquish UPLC (Thermo Fisher Scientific, Massachusetts, United States). Chromatographic separation was achieved on a Thermo Scientific Accucore C_{18} (3 × 100 mm, 2.6 µm) in a thermostatically controlled column compartment (30 °C). The aqueous and organic mobile phases used were acetonitrile (A) and 0.1% phosphoric acid aqueous solution (B), respectively. The gradient elution program was set up as follows: 0-20 min, 12-25% A; 20.1-30 min, 25-28% A; 30.1-32 min, 28-40% A; 32.1-40 min, 40-50% A; 40.1-60 min, 50% A; 60.1-65 min, 12% A. The flow rate was set as 0.3 ml/min, and 2 µl of the extraction was injected into the UPLC system. The instrument was operated in the positive ion mode to perform full-scan analysis over an m/z range of 100-1,500. The optimized parameters were set as follows: a sheath gas flow rate of 35 L/min; a spray voltage of 3000 V; a capillary temperature of 320 V; an aux gas flow rate of 10.00 L/min; a max spray current of 100 A; a probe heater temperature of 350 C; and an S-lens RF level of 50.00%.

Establishment of Effective Compounds and the Target Library of BTP

Compounds of BTP were analyzed by UPLC-MS/MS. Subsequently, targets regarding these identified compounds via UPLC-MS/MS were obtained from the online database of SwissTargetPrediction (http://www.swisstargetprediction.ch/) (Daina et al., 2019).

Establishment of the ONFH Target Library

As a common worldwide resource for gene expression studies, the Gene Expression Omnibus (GEO) database (https://www.ncbi. nlm.nih.gov/geo) allows open access to high-throughput gene expression and other functional genomics datasets (Clough and



Barrett, 2016). The GEO database was searched using "osteonecrosis of femoral head" as the keyword. We aimed to find a comparison of gene expression data sets between femoral head samples from patients with ONFH and normal femoral head samples. In order to ensure the stability and credibility of the analysis results, only data sets with a sample size larger than 10 were selected. Finally, only one suitable data set of ONFH was downloaded from the GEO database, namely, dataset GSE123568. In this dataset, 10 normal femoral head samples and 30 ONFH samples were included.

Acquisition of Differentially Expressed Genes

In order to obtain DEGs, dataset GSE123568 was analyzed with GEO2R, which was the official differential expression analysis tool of the GEO database. In this study, the difference with logFC (fold change) \geq 1.3 and *p*-values <0.01 was statistically significant, and the corresponding genes were identified as DEGs.

Construction of the Protein–Protein Interaction Based on Bisogenet

In this study, the protein–protein interaction (PPI) of BTP and DEGs from ONFH were constructed by Cytoscape software (3.7.2). Then, the overlapping PPI network was obtained by using BisoGenet in Cytoscape. The median of three important attribute values, namely, degree, betweenness, and closeness, was employed for screening to obtain the core gene. After two screenings, a PPI network containing 17 nodes and 114 edges was obtained and used for enrichment analysis. The detailed attribute values and screening process of these targets are presented in **Table 3** and **Figure 3**, respectively.

Functional Enrichment and Constructing the Network of BTP-DEGs-Pathway

The Metascape platform (http://metascape.org/gp/index.html) has a comprehensive annotation function and data of gene annotation monthly updated (Zhou et al., 2019). In this study, functional annotation of gene ontology (GO) and KEGG pathways was performed with the Metascape platform. The main biological processes and involved metabolic pathways were analyzed by submitting the core targets of BTP-DEGs from ONFH to Metascape with p < 0.01. Then, the results were saved and visualized by Bioinformatics (http://www.bioinformatics.com.cn/) (Huang, 2009). Afterward, as shown in **Figure 4**, the network of the BTP-DEGs-Pathway was constructed with Cytoscape (3.7.2).

EXPERIMENTAL VALIDATION

Chemicals and Reagents

Fetal bovine serum (FBS), phosphate-buffered saline (PBS), penicillin–streptomycin, 0.25% trypsin–EDTA (1x), and Dulbecco's modified eagle's medium (DMEM) were purchased from GIBCO (Grand Island, NY, United States). A cell counting kit-8 (CCK8) detection kit was purchased from the Beijing 4A Biotech Co., Ltd. (Beijing, China). The assay kits for DCFH-DA, horseradish peroxidase (HPR)-conjugated secondary antibodies, β -actin, BCA protein assay reagents, and primary antibodies for cleaved (C) caspase-3 were purchased from Boster Biol. Tech. (Wuhan, China). Primary antibodies for phosphorylation- (p-) Akt, Akt, PI3K, and P-PI3K were obtained from ImmunoWay Biotechnology Co. (Suzhou, China). Annexin V-FITC/PI apoptosis kits were obtained from US Everbright[®] Inc

TABLE 1	Precursor	and	product	ions of	constituents	in	the	Ruxue	Tonaluo Pill
	1100001001	ana	produot	10110 01	00110111001110			Danao	rongiao i m.

No.	Compound	RT	Formula	MS ¹	MS ²	Herbal medicine	Ref.
1	DL-Arginine	1.19	$C_6H_{14}N_4O_2$	175 [M + H] ⁺	116, 71, 70, 60	P. aspergillum	(Zhang et al., 2017)
2	Asparagine	1.23	C ₄ H ₈ N ₂ O ₃	131 [M-H]⁻	114, 113, 95, 72	A. membranaceus	(Liu et al., 2013)
3	Choline	1.24	C ₅ H ₁₃ NO	104 [M + H] ⁺	60	A. membranaceus	(Wu et al., 2020)
4	Sucrose	1.25	C12H22O11	729 [2M + FA-H]	683.625, 387.11475, 179.89	A. membranaceus	(Wu et al., 2020)
5	Adenine	1.26	C ₅ H ₅ N ₅	136 [M + H]+	119, 109	P. aspergillum	(Wu et al., 2020)
6	Guanine	1.33	C ₅ H ₅ N ₅ O	152 [M + H] ⁺	135, 110, 81, 55	P. aspergillum	(Zhang et al., 2017)
7	Guanosine	1.33	$C_{10}H_{13}N_5O_5$	284 [M + H] ⁺	152, 135,110	P. aspergillum	(Zhang et al., 2017)
8	Hypoxanthine	1.34	$C_5H_4N_4O$	137 [M + H] ⁺	119, 110	P. aspergillum	(Zhang et al.,
9	Nicotinic acid	1.37	$C_6H_5NO_2$	124 [M-H] ⁻	96, 80, 78, 52	P. aspergillum	(Zhang et al.,
10	Phenylalanine	1.41	$C_9H_{11}NO_2$	166 [M + H] ⁺	120, 103	P. aspergillum	(Zhang et al.,
11	Succinic acid	1.46	$C_4H_6O_4$	117 [M-H] ⁻	99, 73	P. aspergillum	(Zhang et al.,
12	Tryptophan	2.44	$C_{11}H_{12}N_2O_2$	205 [M + H] ⁺	188, 170, 159, 142, 132, 130, 118	P. aspergillum	(Zhang et al., 2017)
13	Caffeic acid	3.01	$C_9H_8O_4$	179 [M-H] ⁻	135	A. sinensis/P. notoginseng	(Liu et al., 2017)
14	Benzoic acid	5.19	C ₇ H ₆ O ₂	121 [M-H] ⁻	93	A. sinensis	(Liu et al., 2017)
15	3-Coumaric acid	6.47	C ₉ H ₈ O ₃	163 M-H]⁻	119, 93	P. notoginseng	(Liu et al., 2019)
16	Calycosin-7-Ο-β-D- glucoside	7.37	C ₂₂ H ₂₂ O ₁₀	447 [M + Na] ⁺	285, 270	A. membranaceus	(Zhang et al., 2008)
17	Chlorogenic acid	8.08	C ₁₆ H ₁₈ O ₉	355.10 [M + H] ⁺	191, 179, 173	A. sinensis	(Liu et al., 2017)
18	Liquiritin	8.12	C ₂₁ H ₂₂ O ₉	417 [M-H]	255, 135, 119	G. uralensis	[Meng et al., 2010]
19	Ferulic acid	13.24	C ₁₀ H ₁₀ O ₄	195 [M + H] ⁺	177, 145	A. sinensis	(Chen et al., 2009)
20	Isoliquiritin	14.99	C ₂₁ H ₂₂ O ₉	419 [M + H] ⁺	257, 147, 137	G. uralensis	(Zhang et al., 2011)
21	Daidzein	15.31	$C_{15}H_{10}O_4$	255 [M + H] ⁺	137.91	A. membranaceus	[Meng et al., 2010]
22	Ononin	17.11	C ₂₂ H ₂₂ O ₉	431 [M + H] ⁺	268	A. membranaceus	(Luo et al., 2020)
23	Formononetin	17.34	C ₁₆ H ₁₂ O ₄	269 [M + H] ⁺	254, 237,137	A. membranaceus	(Luo et al., 2020)
24	Ginsenoside Re	17.41	C ₄₈ H ₈₂ O ₁₈	991 [M-H]	789, 441	P. notoginseng	(Liu et al., 2004)
25	Biochanin A	19.06	C ₁₆ H ₁₂ O ₅	285 [M + H] ⁺	270, 253	A. membranaceus	(Luo et al., 2020)
26	Licoricesaponin G2	31.46	$C_{42}H_{62}O_{17}$	837 [M-H]⁻	351,113	G. uralensis	(Meng et al., 2009)
27	Psoralen	32.23	C11 H6 O3	186 [M + H] ⁺	187.03, 131.04	P. notoginseng	(Yang et al., 2010)
28	Ginsenoside Rb1	33.90	C54H92O23	1,107.59 [M-2H] ²⁻	945.54, 783.48, 621.43	P. notoginseng	(Liu et al., 2004)
29	Pimpinellin	34.20	C ₁₃ H ₁₀ O ₅	247 [M + H]+	231,217,203,186,176	A. membranaceus	(Liu et al., 2012)
30	Gypenoside XVII	34.27	C ₄₈ H ₈₂ O ₁₈	991 [M-H]	945.54, 783.48, 621.43	P. notoginseng	(Jia et al., 2019)
31	Isoliquiritigenin	34.96	C ₁₅ H ₁₂ O ₄	257 [M + H]+	147, 137	G. uralensis	(Zhao et al., 2016)
32	Glycyrrhizic acid	34.97	C42H62 O16	821 [M-H]	645, 351	G. uralensis	(Liu et al., 2004)
33	Licochalcone A	39.42	$C_{21}H_{22}O_4$	339 [M + H]+	297, 121	G. uralensis	(Zhang et al., 2011)
34	Z-Ligustilide	41.13	C ₁₂ H ₁₄ O ₂	232.13 [M + ACN + H] ⁺	191, 173	A. sinensis	(Sheng et al., 2020)

MW, molecular weight, C7DG, calycosin-7-O-β-D-glucoside.

(Suzhou, China). Polyvinylidene fluoride (PVDF) membranes were purchased from Sigma-Aldrich (Shanghai, China). 5,5',6,6'-Tetrachloro-1.1',3.3'-tetraethyl-imidacarbocyanine iodide (JC-1) was obtained from Jiangsu KeyGen Biotech (Nanjing, China).

Cell Culture

The RAW 264.7 cells were purchased from Wuhan Pu-nuo-sai Life Technology Co., Ltd. (Wuhan, China) and used throughout the study. The RAW264.7 cells were cultured in DMEM

containing 10% FBS (v/v) and 1% penicillin–streptomycin (v/ v) at 37°C in a humidified atmosphere of 5% $\rm CO_2.$

Cell Activity Detection

The RAW 264.7 cells were incubated in 96-well plates $(1\times10^4$ cells/well) with different concentrations (0, 5, 10, 20, 40, 60, 80, 100, 150, and 200 µg/ml) of BTP, followed by induction with RANKL (100 ng/ml). After incubation for 24 and 48 h, the supernatant was discarded, and the cells were washed three

TABLE 2 | Active compounds of the Buxue Tongluo Pill.

ld	Molid	Name	Structure
DG1	MOL000414	Caffeic acid	
DG2	MOL004781	Pimpinellin	
DG3	MOL002122	Z-Ligustilide	H
DG4	MOL000360	Ferulic acid	O OH H H O OH
DG5	MOL001955	Chlorogenic acid	
DG6	MOL000219	Benzoic acid	O OH
HQ1	MOL001788	Adenine	$NH_2 H N N$
HQ2	MOL000391	Ononin	HO HO HO O HO O HO
HQ3	MOL000510	Biochanin A	HO (Continued on following page)

TABLE 2 | (Continued) Active compounds of the Buxue Tongluo Pill.

ld	Molid	Name	Structure
HQ4	MOL000392	Formononetin	HOLO
HQ5	MOL000842	Sucrose	HO HO HO HO HO HO HO HO HO HO HO HO HO H
HQ6	MOL009290	Calycosin-7-Ο-β-D-glucoside	HO HO HO HO HO HO HO HO HO HO HO HO HO H
HQ7	MOL000429	Asparagine	H ₂ N O O H ₂ N OH
HQ8	MOL000390	Daidzein	HOLOOH
DL1	MOL000346	Succinic acid	но он
DL2	MOL001831	Hypoxanthine	
DL3	MOL000054	dL-Arginine	
DL4	MOL000421	Nicotinic acid	O OH
DL5	MOL001757	Guanine	

(Continued on following page)

TABLE 2 | (Continued) Active compounds of the Buxue Tongluo Pill.

ld	Molid	Name	Structure
DL6	MOL002687	Guanosine	
DL7	MOL000041	Phenylalanine	
DL8	MOL001780	Tryptophan	O OH
DL9	MOL001788	Adenine	NH ₂ N
GC1	MOL004903	Liquiritin	
GC2	MOL001789	Isoliquiritigenin	HO OH
			OH
GC3	MOL004951	Isoliquiritin	
GC4	MOL004876	Glycyrrhizic acid	
			$\begin{array}{c} \underline{\varphi} & \underbrace{\varphi} & $

(Continued on following page)

TABLE 2 | (Continued) Active compounds of the Buxue Tongluo Pill.

ld	Molid	Name	Structure
GC5	MOL000497	Licochalcone A	HO H OH
GC6	MOL004892	Licoricesaponin G2	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} $
SQ1	MOL000414	Caffeic acid	
SQ2	MOL004549	3-Coumaric acid	O OH H H
SQ3	MOL001950	Psoralen	
SQ4	MOL007495	Gypenoside XVII	HO HO HO HO HO HO HO HO HO HO HO HO HO H
SQ5	MOL007476	Ginsenoside Rb1	

(Continued on following page)

TABLE 2 | (Continued) Active compounds of the Buxue Tongluo Pill.



times with PBS. Then, $10 \ \mu$ l CCK-8 was added to each well and incubated for 0.5 h. The optical density (OD) values were measured at 450 nm by the microtablet reader (Bio-RAD, United States). Each experiment was repeated three times. The concentration- and time-dependent effects of BTP on raw 264.7 cells are presented in **Figure 5**.

Osteoclastogenesis and TRAP Staining

The RAW 264.7 cells were seeded in 24-well plates $(1 \times 10^5 \text{ cells}/\text{ well})$ and then pretreated with BTP (0, 50, 75, and 100 µg/ml) for 24 h, followed by induction with RANKL (100 ng/ml) for 7 days. Untreated cells were used as a negative control, while only

RANKL-induced cells were used as a positive control group. During the induction period, the medium was changed every other day. After 7 days, the cells were washed with PBS, followed by fixing with 4% paraformaldehyde for 30 min, and then stained to detect TRAP activity. Finally, trap-positive cells were enumerated via a microscope. Mature osteoclasts with more than three nuclei were counted in a random area in each replicate sample.

Bone Resorption Assay

The RAW 264.7 cells were seeded in 96-well plates $(1 \times 10^4 \text{ cells}/\text{ well})$ containing bovine bone slices and then pretreated with



different concentrations of BTP (0, 50, 75, and $100 \mu g/ml$) for 24 h, followed by induction with RANKL (100 ng/ml) for 9 days. Then, bovine bone slices seeded with cells were washed with PBS, fixed in 2.5% glutaraldehyde over 10 min, ultrasonically cleaned with 0.25 mol/l ammonia hydroxide, and stained with 1% toluidine blue over 10 min. After washing with ddH2O, the osteolysis pits were photographed with a light microscope. Bone resorption capacity was defined as the bone resorption relative area (resorption area/total bone area).

Apoptosis Assay Using a Flow Cytometer

Cell apoptosis was detected by flow cytometry (CytoFLEX FCM, Beckman Coulter Inc., Atlanta, Georgia, United States). The RAW 264.7 cells were incubated in 6-well plates with RANKL (100 ng/ml) for 5 days and then treated with BTP (0, 50, 75, and 100 μ g/ml) for 24 h. Subsequently, cell apoptosis was detected with the manufacturer's instructions of the Annexin V/PI apoptosis kit and cell cycle kit; the cells were stained with Annexin V-FITC and PI, respectively, and then detected by flow cytometer analysis. Each experiment was repeated three times.

Mitochondrial Membrane Potential (MMP) Determination

The change of intracellular mitochondrial membrane potential (MMP, $\Delta \Psi m$) is generally recognized as an important indicator of mitochondrial dysfunction, and JC-1 is commonly considered as an ideal probe to evaluate $\Delta \Psi m$. In this study, the cells were inoculated in laser confocal dishes (1×10⁴/well), treated with different concentrations of BTP for 24 h, and subsequently induced with RANKL (100 ng/ml) for 5 days. After the induction, the cells were incubated with the JC-1 probe (10 µg/ml) in the dark for 30 min. Confocal laser microscopy was used to observe the green and the red fluorescence (Leica, SP8 SR, Wetzlar, Germany) of cells at 488 and 647 nm, respectively, and the images were recorded.

Immunofluorescence Assay of AKT/P-AKT

The RAW 264.7 cells were seeded in the confocal dish (1×10^5) and processed as described above. Then, they were washed three times with PBS, fixed with 4% paraformaldehyde for 30 min, and then washed three times with PBS. Afterward, the cells were treated with 0.5% Triton-X-100 for 30 min, followed by blocking with goat serum for 1 h at room temperature, and then, PI3K and P-PI3K antibodies (1:500) were added separately and incubated overnight at 4°C. Soon afterward, antirabbit IgG (H&L) Alexa Fluor[®] 488 and antimouse IgG (H + L) Alexa Fluor[®] 647 were added and incubated at room temperature for 1 h in the dark. Then, PBS was used to wash out the unbound secondary antibody, and the nuclei were stained with DAPI. Then, AKT/P-AKT and their fluorescence intensity were observed using a confocal laser microscope (Leica, SP8 SR, Wetzlar, Germany).

Western Blotting Assay

The RAW 264.7 cells were inoculated in 6-well plates (2×10^6) well) at 37°C in a humidified atmosphere of 5% CO2 and incubated for 24 h. Then, the RAW 264.7 cells were treated with RANKL (100 ng/ml) for 5 days and then treated with BTP (50, 75, and 100 µg/ml) for 24 h. At the end of the treatment, 100 µl of RIPA cell lysates was used to extract the total cell protein. The protein concentrations were determined using BCA protein assay reagents. Then, the total protein was separated by 12% SDS-PAGE and then transferred to the PVDF membrane. After blocking by 5% skimmed milk, the PVDF membrane was incubated overnight with diluted primary antibodies of PI3K, P-PI3K, C-caspase-3, Akt, and p-Akt (dilution 1:1,000) at 4°C. Subsequently, the PVDF membrane was incubated for 1 h with the diluted secondary antibody. Finally, the protein bands were stained with ECL detection kits, and β -actin was used as the internal reference. Image analysis software ImageJ (version 1.51, National Institutes of Health, MD, United States) was utilized for gray analysis.

Statistical Analysis

All the data were presented as the mean \pm standard deviations (SDs), statistical comparisons were evaluated using one-way analysis of variance (ANOVA), and significant differences between the mean values were measured using Duncan's multiple range test. p < 0.01 was deemed statistically significant.

RESULTS

Effective Compounds of BTP

A total of 34 components were identified from BTP, of which six compounds belonged to *Angelica sinensis* (Oliv.) Diels, seven to *Astragalus membranaceus* (Fisch.) Bge, six to *Glycyrrhiza uralensis* Fisch., six to *Panax notoginseng* (Burk.) F. H. Chen, and nine to *Pheretima aspergillum* (E.Perrier). Their specific information and total ion current diagram are shown in **Table 1**, **Table 2**, and **Figure 2**, respectively. Moreover, a total of 1,232 related targets were obtained from the online databases.

Establishment of the ONFH Target Library

A total of 178 DEGs were screened out, including 143 upregulated genes and 35 downregulated genes, and were visualized with a volcano plot, as shown in **Figure 2**. In the volcano plot, the vertical axis represents \log_2 FC (fold change), and the horizontal axis represents $\log_{10} (p$ -value). The DEGs with \log_2 FC > 0 were defined as upregulated genes, and the others were downregulated genes. Additionally, the expression situation regarding all the DEGs was visualized with a heatmap, as shown in **Figure 3A**. In the heatmap, the vertical axis represents DEGs, while the horizontal axis represents the sample. DEGs were effectively divided into normal and ONFH groups. Red indicates the upregulated genes, and green represents the downregulated genes.

Acquisition of Core Genes Regarding BTP Against ONFH

Centrality expresses the degree of a node in a certain network in the center of the whole network. The degree is defined as the sum of direct connections between nodes and represents the cohesion of a given node in a certain network. Furthermore, betweenness indicates the number of shortest paths passing through a node. These three factors are the indispensable basis for assessing the importance of a specific target. Through screening, 17 core targets with 114 vital interactions were obtained, and the detailed information and identification process of core targets are shown in **Table 3** and **Figure 3C**, respectively.

Functional Enrichment of Core Targets

The signal pathway of core targets was analyzed using the Metascape platform, and the results were visualized by bioinformatics. The results showed that the functions of core targets were closely related to the occurrence of ONFH. KEGG and GO enrichment are presented in **Table 4** and **Figure 4**, respectively.

Based on the results of KEGG enrichment, as shown in **Table 4**, multiple pathways jointly contributed to the antiONFH effect of BTP, including the PI3k-Akt signaling pathway, prostate cancer, pathways in cancer, the cell cycle, the estrogen signaling pathway, protein processing in the endoplasmic reticulum, hepatitis c, proteoglycans in cancer, the central carbon metabolism in cancer, small-cell lung cancer, progesterone-mediated oocyte maturation, endocrine resistance, oocyte meiosis, fluid shear stress and atherosclerosis, and breast cancer. Thus, it suggested that the antiONFH effect of BTP might associate with a synergistic effect of multiple pathways.

In conformity with the results of GO enrichment, the biological processes (BPs) in which BTP chiefly participated involved DNA repair, cell cycle phase transition, regulation of cell cycle phase transition, regulation of the cell cycle process, mitotic cell cycle G1/S transition, cell cycle G1/S phase transition, mitotic cell cycle phase transition, positive regulation of the cell cycle, the DNA biosynthetic process, response to topologically incorrect protein, protein insertion into the membrane, the proteasome-mediated ubiquitin-dependent protein catabolic process, regulation of cell cycle G2/M phase transition, and developmental growth involved in morphogenesis.

Such effects were primarily reflected in several aspects, including ubiquitin-protein ligase binding, ubiquitin-like protein ligase binding, nitric-oxide synthase regulator activity, disordered domain specific binding, kinase binding, protein kinase binding, protein domain specific binding, protease binding, cell adhesion molecule binding, histone deacetylase binding, unfolded protein binding, integrin binding, protein phosphatase binding, phosphatase binding, and chromatin binding. The targets of this action were chiefly concentrated in multiple cell sites, including vesicle lumen, melanosomes, pigment granules, secretory granule lumen, cytoplasmic vesicle lumen, the perinuclear region of the cytoplasm, ficolin-1-rich granule lumen, the intracellular protein-containing complex, focal adhesion, the cell-substrate junction, growth cones, neuronal cell bodies, sites of polarized growth, ficolin-1-rich granules, and the protein-DNA complex.

Based on the above bioinformatics analysis, previous reports, and our preliminary experiments, we deduced that the molecular mechanisms of this TCM formula might attribute to PI3K/Aktrelated cell apoptosis.

Construction of Key Targets-Pathway Network

The network of key targets-pathway was constructed with Cytoscape (3.7.2), as presented in **Figure 3B**. V represents the pathway, and the diamond represents the DEGs. The greater the significance, the larger the volume of the graph was. The results showed that the targets of TP53, EGFR, and CDK2 and the pathways of the PI3K-AKT signaling pathway and cell cycle were more critical in the entire network. Therefore, subsequent experiments chose these two pathways for verification.

Cytotoxic Effect of BTP on RAW264.7 Cells

The cytotoxicity of BTP on normal RAW 264.7 cells was assessed by CCK-8 assays. As shown in **Figure 5**, BTP at concentrations up to 200 mg/ml did not exhibit obvious cytotoxicity on RAW264.7 cells within 24 and 48 h of incubation.

BTP Inhibits Osteoclastogenesis and Bone Resorption in Osteoclasts

At 7 days after inducting RAW 264.7 cells with RANKL (100 ng/ ml), TRAP-positive multinucleated cells were observed under a light microscope, as shown in **Figure 6**. Interestingly, BTP at 20, 40, and 80 µg/ml markedly decreased the number of osteoclasts in a dose-dependent manner (p < 0.05 at 100 µg/ml, p < 0.005 at 200 µg/ml, p < 0.0001 at 400 µg/ml). In addition, the significant inhibitory effect of BTP on bone resorption *in vitro* has also been confirmed. As shown in **Figure 8**, compared with the control group, BTP dose-dependently reduced the area of bone resorption.

BTP Induces Cell Apoptosis in Osteoclasts

In this study, two comprehensively recognized cell apoptosis detection methods, including AO-EB double staining and FITC-conjugated Annexin V/PI staining, were carried out using a laser confocal microscope and flow cytometry analysis. Therefore, we further explored the apoptosis induced by BTP treatments. As shown in **Figure 7A**, our present results confirmed our hypothesis. After 5 days of RANKL treatment, the RAW 264.7 cells were induced to osteoclasts. As shown in **Figure 7A**, BTP at the concentrations of 50, 75, and 100 µg/ml could induce apoptosis in osteoclasts, compared to the control osteoclasts. Moreover, the results of immunofluorescence also presented the same trend. As far as we know, JC-1 aggregates in the mitochondrial matrix to form polymers that emit red fluorescence under normal physiological conditions and green fluorescence when MMP is reduced. Thus, the changes of $\Delta\Psi$ m

TABLE 3 | Detailed attribute values of core targets.

Name	Degree	Betweenness	Closeness
TP53	417	8838.351	0.625
EGFR	413	4978.824	0.584532
ESR1	362	4732.667	0.595238
YWHAZ	354	5282.821	0.602968
FN1	401	5764.932	0.616114
UBC	421	7284.354	0.608614
NTRK1	715	15501.89	0.680628
CUL3	519	8497.666	0.643564
CUL1	331	4143.496	0.604651
CDK2	352	5856.056	0.605778
COPS5	364	4224.348	0.605214
HSP90AB1	304	3368.986	0.577265
ITGA4	298	3802.689	0.592525
HSP90AA1	368	3823.474	0.587703
VCP	301	3662.213	0.579839
NPM1	291	3407.6	0.590909
MCM2	403	6534.106	0.617871

could be directly reflected by the fluorescence transformation. In **Figure 7B**, compared with the control group, the green fluorescence of the experimental group was getting stronger, while the red fluorescence was getting weaker, indicating that MMP breakdown happened.

The results suggested that BTP (50, 75, and 100 μ g/ml) could induce remarkable apoptosis in osteoclasts (RANKL induced RAW 264.7 cells). Furthermore, the apoptosis markers of C-caspase-3, bcl-2, and bax were determined. As shown in **Figure 8**, BTP could upregulate the expression of C-caspase three and bax, downregulating bcl-2 expression in osteoclasts in a dose-dependent manner.

BTP Regulates the PI3K/AKT Signal Pathway in Osteoclasts

The PI3K/Akt pathway is a classical signaling pathway responsible for regulating cell proliferation, differentiation, apoptosis, and a



TABLE 4 | Functional enrichment of the core targets of BTP-DEGs.

KEGS PIR-64 signaling pathway 0 2.882-13 S24117641 Protate across 7 1.786-09 41.1784-09 Pathways in nancer 7 1.786-19 91.11784-09 Coll open 2.8117641 23.5291171 Pathways in nancer 4 2.806-19 23.5291171 Protein processing in androg sensing refloxium 4 2.806-10 23.5291171 Protein processing in androg sensing refloxium 5 2.8171670 71.747058 Contral carbon metabolism in cancer 3 2.737260 17.6470588 Properature molitad coopis maturation 3 2.2211160 17.6470588 Coll Properature molitad coopis maturation 1.888-10 1.888-10 1.888-10 Propate across	Term	Category	Count	p Value	Gene ratio
Prostance and a first of the second	KEGG	PI3K-Akt signaling pathway	9	2.982E-13	52.94117647
Pathways naroor 7 1.486.00 41.1747103 Coll cycle 5 0.465.00 29.411267 Entrogen signaling pathway 4 3.06167 23.5201172 Hotain processing in ordcourse relactum 4 2.00160 23.5201172 Hotain processing in ordcourse relactum 3 7.07060 7.17470583 Control carbon 3 7.07060 7.17470583 Small cell large carbon 1.0886-05 7.16470583 Propertemmendated coxplematization 3 2.2217-05 7.17470583 Corp indices 3 8.1047-05 7.47470588 Corp indices 3 8.4167-05 7.47470588 Corp indices 3 8.4167-05 7.47470588 Corp indices 3 8.4167-05 7.474705884 Corp indices 3 8.4476-05 7.47470588 Corp indices 1.0487-05 7.44770588 Corp indices 1.4487-05 7.44770588 Corp indices 1.4487-05 7.44770588 Corp indices 1.4487-		Prostate cancer	5	1.505E-09	29.41176471
Coll optimin processing in endparamer reficulum 4 9.31696-07 233.5941179 Protein processing in endparamer reficulum 4 2.410-06 233.5941179 Protein processing in endparamer reficulum 4 2.410-06 233.5941179 Protein processing in endparamer reficulum 3 0.21690-06 233.5941179 Protein processing in endparamer reficulum 3 0.22811-05 0.7747-0588 Endpartme resistance 3 0.20811-04 0.7747-0588 End		Pathways in cancer	7	1 745E-09	41 17647059
 Sistops signaling asthway Sistops signaling asthway Sistops signaling asthway Sistops signaling asthway Sistops signaling signaling asthway Sistops signaling signaling asthway Sistops signaling s			5	9 05E-09	29 /1176/71
GO EP		Estrogon signaling nathway	4	3 160E 07	23.520/1176
GO EP 2 0.502:11 2 0.502:11 GO MF 4 0.502:02 2.502:11 GO MF 0.502:02 17.471:050 GO MF 0.502:02 0.502:02 GO MF 0.502:02 0.502:02 GO MF 0.502:02 0.502:02 MA regulation of the cell cycle maturation 3 0.502:02 MO A regulation of the cell cycle maturation 3 0.511:02 Model maturation 3 0.511:02 0.702:02 Model maturation 6 0.522:06 0.702:02 Model maturation 6 0.522:06 0.702:02 Model maturation 7 0.522:06 0.702:02 Model maturation 6 0.522:06 0.702:02 Model maturation 7 0.522:06 0.702:		Estrogen signaling painway	4	3.109E-07	23.32941170
Pripting C. 4 2.0000-00 2.0000-00 Printeglycaus in cancer 3 7.7787-06 17.74470882 Central carbon metabolem in cancer 3 2.0017-06 17.74470882 Progestance-metabole cocyte maturation 3 2.0017-06 17.74470882 Donyte metois 3 2.0017-06 17.74470882 Donyte metois 3 3.0167-05 17.74470882 CO UP Brass cancer 3 3.0167-05 17.74470882 CO UP India their stress and atherosolerosis 3 3.0167-05 17.74470882 CO UP India their stress and atherosolerosis 3 3.0167-05 17.0470882 CO UP India their stress and atherosolerosis 3 3.0177-06 17.74470882 CO UP India their stress and atherosolerosis 3 3.0127-06 17.0470882 CO UP India their stress and atherosolerosis 3 3.0127-07 1.0007-07 India their stress and atherosolerosis India their stress and atherosolerosis 3 3.0027-07 India their stress and atherosoleros		Protein processing in endoplasmic reliculum	4	2.61E-06	23.52941170
Protestypen in cancer a 4 5.7085-06 72.42470586 Small oil ung cancer 3 7.7975-06 71.44470586 Small oil ung cancer 3 2.6271-65 71.74470586 Endocrine metablane incancer 3 2.6271-65 71.74470586 Part al hear stress and attenuclarosis Endocrine metablane incancer 3 2.6271-65 71.74470586 Part al hear stress and attenuclarosis Endocrine metablane incancer 3 2.6271-65 71.74470586 Part al hear stress and attenuclarosis Endocrine metablane incancer 3 2.6271-65 71.74470586 Part al cycle phase transition 3 2.6271-65 71.74470586 Part al		Hepatitis C	4	2.802E-06	23.52941176
Central carbon metabolism in carbon 3 7.737E-06 17.64705886 Small coll lug carbon 3 2.821E-05 17.64705886 Progeserance-mediated coxyte maturation 3 2.821E-05 17.64705886 Coxyte medias 3 5.101E-05 17.64705886 Coxyte medias 6 5.331E-10 1.339E-08 Coxyte process 8 7.122E-08 1.44586 Coxyte ol (3) phase transition 6 7.232E-08 1.44586 Initiatic call cycle phoses 8 7.122E-08 1.44586 Coxyte ol (3) phase transition 7 2.339E-08 1.445867 Initiatio call cycle phoses 6 1.245867 1.445877 protein inserie transition 7 2.339E-08 1.44567 Initiatio call cycle phoses 6 1.245877 1.44577 protein infinitio call cycle pho		Proteoglycans in cancer	4	5.796E-06	23.52941176
GO IP Organization mediated cocyle mutuation Society emutuation Society emutuatis Society emutuation Society emutuation Society emutuation Society		Central carbon metabolism in cancer	3	7.797E-06	17.64705882
Progestational-mediated cocyte maturation32.521E-0517.74770588Endocrine resistance35.410E-0517.74770588Ocyte misois35.101E-0517.74770588Breast cancer38.104E-0517.74770588Breast cancer35.032E-0117.84770588Breast cancer35.032E-0117.84770588C/O EPPColl cycle phase transition85.032E-01C/O EPPColl cycle phase transition87.122E-03C/O EPPColl cycle phase transition72.932E-03C/O EPPColl cycle phase transition67.962E-03C/O EPPColl cycle phase transition72.932E-03D/N biosyntheir phase transition51.148E-07D/N biosyntheir phase transition51.148E-07Provien inserting phase transition61.223E-07Provien inserting phase transition51.148E-07Provien inserting phase transition51.148E-07Provien inserting phase transition61.223E-01C/O MFulcquith-like proven ligaes brinding95.038E-14Ulcquith-like proven ligaes brinding95.038E-14C/O MFulcquith-like proven ligaes brinding75.902E-03Ulcquith-like proven ligaes brinding34.102E-05Protea doman specific brinding34.102E-05Protea doman specific brinding33.332E-05Protea doman specific brinding33.332E-05Protea brinding		Small cell lung cancer	3	1.689E-05	17.64705882
Endocrine resistance32.421E-0517.9475088Oxpet meosis38.447E-0517.9475088Fuld shear stress and atherosolerosis38.447E-0517.9475088Endocrine resistance86.337E-106.322E-09DNA repar86.339E-016.322E-09CGO EPCall cycle phase transition76.522E-09CGO EPCall cycle phase transition76.322E-09CGO EPCall cycle phase transition72.330E-08CGO EPCall cycle phase transition72.330E-08CGO EPCall cycle phase transition72.330E-08CGO EPCall cycle phase transition72.330E-08CGO EPCall cycle phase transition69.430E-07CGO EPCall cycle phase transition69.430E-07CGO EPCall cycle click phonese transition61.434E-07CGO EPCall cycle click phonese t		Progesterone-mediated oocyte maturation	3	2.521E-05	17.64705882
COOPE35416E.6617.64705885Fluid shear stress and attransactorosis381.04E.6517.64705885Breast cancer356.81E.101COOPEregulation of the cell cycle process87.122E.08ord cycle prises transition87.122E.081ord cycle prises transition87.122E.081ord cycle prises transition87.122E.081ord cycle prises transition67.982E.081ord cycle prises transition67.982E.081ord cycle prises transition67.982E.081ord cycle prises transition67.982E.081problem insertion into the membrane41.149E.071problem insertion into the membrane81.149E.071problem insertion into the membrane81.149E.071problem insertion into the membrane81.149E.071ord cycle cycle transition61.395E.081ord cycle cycle transition81.149E.071ord cycle cycle transition81.149E.071ord cycle cycle transition92.885E.141ord cycle cycle transition81.149E.071ord cycle cycle transition81.149E.071ord cycle cycle transition81.149E.071ord cycle cycle transition81.149E.071ord cycle cycle transition92.839E.141ord cyc		Endocrine resistance	3	2.521E-05	17.64705882
Puck there stress and atherosolences38, 104E-0617, 84705882GO BPDNA repair85, 631E-1017, 84705882ordi cycle phase transition76, 522E-0910regulation of the end cycle process82, 294E-0910GI X5 transition of the mitotic call cycle82, 294E-0910intotic call cycle phase transition81, 488E-0810intotic call cycle phase transition61, 488E-0810positive regulation of the call cycle67, 982E-0810DNA biosyntheic process72, 986-0810intotic call cycle phase transition51, 149E-0710protein instruct call cycle phase transition51, 149E-0710regulation of the call cycle phase transition51, 149E-0710regulation of the call cycle 2/M phase transition51, 588E-0710ordi cycle 2/M phase transition51, 588E-0710regulation of tal cycle 2/M phase transition51, 588E-0710regulation of tal cycle 2/M phase transition51, 588E-0710regulation of tal cycle call cycle		Oocyte meiosis	3	5.416E-05	17.64705882
Brast cancer38.447E.0517.64705882GO EPDNA repairs transition86.338E.16.10regulation of oel cycle phase transition76.522E.09G1/S transition of the nell cycle process87.122E.09and cycle phase transition72.036E.08and cycle phase transition72.036E.08and cycle phase transition72.036E.08mittoi cell cycle phase transition72.036E.08DNA bosynthetic process59.438E.09protein insertion into the membrane41.196E.07protein insertion into the membrane41.196E.07regulation of mitolic cell cycle phase transition61.484E.07regulation adity41.162E.03regulation adity41.162E.03regulation adity41.162E.03regulation adity41.162E.03regulation adity41.162E.03regulation adity41.162E.03regulation adity41.162E.03regulation adity41.162E.03regulation adity41.162E.03regulation adity41.16		Fluid shear stress and atherosclerosis	3	8.104E-05	17.64705882
GO BP DNA require 5 5.531E-10 The order of the set of constraints of the set of conset of the set of constrai		Breast cancer	3	8 447E-05	17 64705882
COUDEControlCount <t< td=""><td>CO BD</td><td>DNA ropair</td><td>8</td><td>5.621E 10</td><td>11.04100002</td></t<>	CO BD	DNA ropair	8	5.621E 10	11.04100002
GO VCC Vesice Lange Induction Intervention I	GO DF	DNA repair	0	1,2005,00	
regulation of cell cycle phase transition 7 6.2224-09 regulation of the cell cycle process 8 7.1225-09 G1/St transition of the mittolic cell cycle 6 9.2984-09 cell cycle G1/St phase transition 7 2.9985-08 postte regulation of the cell cycle 6 7.9925-08 postte regulation of the cell cycle 6 7.9925-08 protein insertion into the membrane 4 1.1985-07 regulation of cell cycle phase transiton 6 1.2435-07 regulation of cell cycle d2/M phase transiton 6 1.2435-07 regulation of cell cycle d2/M phase transiton 6 1.2435-07 regulation of cell cycle d2/M phase transiton 6 1.2435-07 regulation of cell cycle d2/M phase transiton 6 1.2435-07 regulation of cell cycle d2/M phase transiton 5 1.598E-07 regulation of cell cycle d2/M phase transiton 5 1.598E-07 regulation d1 cell cycle d2/M phase transiton 5 1.598E-07 regulation d1 cell cycle d2/M phase transiton 5 1.598E-07 regulation d1 cell cycle d2/M phase t			8	1.399E-09	
GO MF (1/5 transition of the role cycle process) 8 (2,224E-09 cell cycle C1/5 phase transition 7 (2,396E-08 positive regulation of the cell cycle positive regulation of the cell cycle positive regulation of the cell cycle protein insection in the membrane 7 (2,396E-08 DNA biosynthetic process) 5 (3,436E-08 response to the topologically incorrect protein 1 response to the topologically incorrect protein 1 response to the topologically incorrect protein 1 regulation of motio cell cycle phase transition 6 (1,248E-07 regulation of motio cell cycle phase transition 7 regulation of motio cell cycle c2M phase transition 7 regulation of motio cell cycle c2M phase transition 7 regulation of motio cell cycle c2M phase transition 7 regulation of anni specific binding 9 rotein kinase binding 9 protein kinase binding 7 protein comain specific binding 7 protein kinase binding 7 protein comain specific binding 7 protein binding 7 protein phosphatase binding 7 protein p		regulation of cell cycle phase transition	1	6.522E-09	
G1/5 transition of the mitotic cell cycle69.8484-09netl cycle 1/5 kpase transition72.808E-08postive regulation of the cell cycle67.862E-08DNA biosynthetic process51.149E-07protein insection into the membrane41.196E-07protein insection into the membrane41.196E-07regulated of the topologically incorrect protein catabolic process61.484E-07regulation of cell cycle phase transition61.484E-07regulation of cell cycle phase transition51.782E-07devicipmental growth involved in morphogenesis51.782E-07devicipmental growth involved in morphogenesis51.782E-07protein domain specific binding78.076E-08protein domain specific binding78.076E-08protein domain specific binding34.012E-05histone deacetylase binding39.108E-05protein domain specific binding34.012E-05histone deacetylase binding39.162E-05Protein domain specific binding33.392E-05 <td< td=""><td></td><td>regulation of the cell cycle process</td><td>8</td><td>7.122E-09</td><td></td></td<>		regulation of the cell cycle process	8	7.122E-09	
cell cycle f1/S phase transition61.498E-08positive regulation of the cell cycle67.298E-08DNA biosynthetic process59.438E-08response to the topologically incorrect protein51.149E-07protein insertion into the membrane61.243E-07regulation of notic cell cycle phase transition51.243E-07regulation of notic cell cycle phase transition51.568E-07developmental growth involved in morphogenesis51.568E-07developmental growth involved in morphogenesis92.858E-14ubiquitin-like protein ligase binding92.858E-14ubiquitin-like protein ligase binding44.168E-09Kinase binding75.033E-14ubiquitin-like protein ligase binding75.033E-08protein disase binding75.033E-08protein domain specific binding34.315E-09kinase binding34.315E-09protein domain specific binding34.313E-05hintore dacatylase binding34.312E-05protein domain specific binding34.312E-05protein domain specific binding33.332E-05protein binding33.332E-05protein domain specific binding33.332E-05		G1/S transition of the mitotic cell cycle	6	9.284E-09	
mitotic cell cycle phase transition72.808E-08positive regulation of the cologically incorrect protein59.438E-08INA biosynthetic process59.438E-08response to the topologically incorrect protein41.198E-07protein instront in the membrane41.139E-07regulation of cell cycle phase transition61.484E-07regulation of cell cycle phase transition61.484E-07regulation of cell cycle phase transition82.855E-14ubiquiti notein lgase binding92.855E-14ubiquiti notein lgase binding92.855E-14ubiquiti notein lgase binding1.148E-07regulation of cell cycle call or adt/fly41.142E-11disordered domain specific binding84.315E-09protein kinase binding78.076E-08protein kinase binding84.315E-09protein kinase binding84.315E-09protein kinase binding84.315E-09protein kinase binding34.101E-06ell adhesion molecule birding34.102E-05protein kinase binding34.102E-05protein kinase binding34.102E-05protein kinase binding33.332E-05protein phasphatase binding33.332E-05protein kinase binding33.332E-05protein kinase binding33.332E-05protein kinase binding33.332E-05protein birding complex33.332E-05 <td< td=""><td></td><td>cell cycle G1/S phase transition</td><td>6</td><td>1.498E-08</td><td></td></td<>		cell cycle G1/S phase transition	6	1.498E-08	
positive regulation of the cell cycle67.982E-08DNA boogsmithelic process594.986-08response to the topologically incorrect protein51.149E-07protein insertion into the membrane41.198E-107protein membrane diugulin-degenednet protein catabolic process61.243E-07regulation of cell cycle C2M phase transition51.585E-07developmental growth involved in morphogenesis51.782E-07ubiquitin-like protein ligase binding92.855E-14ubiquitin-like protein ligase binding92.855E-14ubiquitin-like protein ligase binding84.315E-09protein domain specific binding75.033E-14nitric-oxide synthase regulator activity41.162E-09Kinase binding75.033E-08protein domain specific binding75.033E-08protein domain specific binding34.912E-05nitric-oxide synthase binding34.912E-05protein domain specific binding39.102E-05protein domain specific binding39.102E-05protein domain specific binding39.102E-05protein binding39.102E-05protein binding33.332E-05protein binding33.332E-05protein binding55.163E-05protein binding55.163E-05protein binding55.163E-05protein binding55.163E-05protein binding55.163E-05 <td></td> <td>mitotic cell cycle phase transition</td> <td>7</td> <td>2.936E-08</td> <td></td>		mitotic cell cycle phase transition	7	2.936E-08	
BNA biosynthetic process59.436E-08response to the topologically incorrect protein41.106E-07protein insertion into the membrane41.106E-07protessome-mediated ubiquin-dependent protein catabolic process61.243E-07regulation of motic cell cycle phase transition61.434E-07regulation of cell cycle phase transition61.558E-07developmental growth involved in morphogenesis51.752E-07GO MFubiquitin-like protein ligase binding92.855E-14ubiquitin specific binding41.142E-11disordered domain specific binding84.315E-09protein kinase binding75.903E-08protein kinase binding75.903E-08protein kinase binding34.105E-06protein kinase binding34.105E-06protein kinase binding34.105E-06protein kinase binding34.105E-06protein domain specific binding34.105E-06unfolded protein binding34.105E-06protein protein domain specific binding39.162E-06protein domain specific binding39.162E-06protein protein binding39.162E-06protein protein binding33.392E-06protein protein protein binding33.392E-06protein protein		positive regulation of the cell cycle	6	7.962E-08	
response to the topologically incorrect protein51.149E-07protein insertion into the membrane41.196E-07proteinsome-mediated ubiquitn-dependent protein catabolic process61.243E-07regulation of mitotic cell cycle phase transition61.848E-07regulation of enl cycle 22M phase transition51.782E-07developmental growth involved in morphogenesis51.782E-07ubiquitn incles protein ligase binding92.865E-14ubiquitn-dependent domain specific binding41.142E-11disordered domain specific binding75.003E-08Protein kinase binding75.003E-08protein kinase binding75.003E-08protein kinase binding75.003E-08protein kinase binding34.015E-06protein kinase binding34.015E-06protein kinase binding34.012E-05protein kinase binding34.002E-05protein binding34.002E-06protein binding34.002E-06protein phosphatase binding33.002E-06protein phosphatase binding33.002E-06protein phosphatase binding33.002E-06protein phosphatase binding33.002E-06protein phosphatase binding33.032E-06protein phosphatase binding33.032E-06protein phosphatase binding33.032E-06protein phosphatase binding33.032E-06protein phosphatase binding <t< td=""><td></td><td>DNA biosynthetic process</td><td>5</td><td>9.436E-08</td><td></td></t<>		DNA biosynthetic process	5	9.436E-08	
protein insertion into the membrane41.196E-07proteasome-mediated ubiquitin-dependent protein catabolic process61.243E-07regulation of notic call occle gode phase transition51.558E-07developmental growth involved in morphogenesis51.782E-07GO MFubiquitin-like protein ligase binding92.855E-14ubiquito not cell cigase binding95.039E-14intite-oxide synthase regulator activity44.142E-11disordered domain specific binding75.903E-08protein kinase binding75.903E-08protein kinase binding78.076E-08protein kinase binding34.105E-06kinase binding34.105E-06protein kinase binding34.105E-06protein kinase binding34.105E-06protein domain specific binding34.105E-06protein domain specific binding34.105E-06protein protein phosphatase binding34.105E-06protein phosphatase binding34.105E-06protein phosphatase binding33.392E-05protein binding33.392E-05protein binding33.392E-05protein binding33.392E-05protein binding33.392E-05protein phosphatase binding33.392E-05protein phosphatase binding33.392E-05protein phosphatase binding33.392E-05perimutaer region of the cytoptasm55.62E-05 </td <td></td> <td>response to the topologically incorrect protein</td> <td>5</td> <td>1.149E-07</td> <td></td>		response to the topologically incorrect protein	5	1.149E-07	
groteasome-mediated ubiquitn-dependent protein catabolic process61.243E-07regulation of mitotic cell cycle phase transition61.848E-07developmental growth involved in morphogenesis51.782E-07developmental growth involved in morphogenesis51.782E-07ubiquitn-like protein ligase binding95.039E-14utirc-oxide synthase regulator activity44.142E-11disordered domain specific binding84.315E-09Kinase binding75.003E-08protein hinase binding75.003E-08protein domain specific binding75.003E-08protein domain specific binding34.101E-06cell adhises binding34.101E-06orell adhises binding34.101E-06orell adhises binding34.101E-06orell adhises binding34.101E-06untoided protein binding34.101E-06untoided protein binding34.101E-06protein phosphatase binding30.0002008protein phosphatase binding33.002E-06protein phosphatase binding33.302E-05protein phosphatase binding complex5 <td></td> <td>protein insertion into the membrane</td> <td>4</td> <td>1 196E-07</td> <td></td>		protein insertion into the membrane	4	1 196E-07	
GO MF instance diagnation of mitotic cell cycle (22M phase transition 6 (1.444E-07) regulation of mitotic cell cycle (22M phase transition 5 (1.588E-07) developmental growth involved in morphogenesis 5 (1.782E-07) developmental growth involved in morphogenesis 9 (2.855E-14) ubiquitin-like protein ligase binding 9 (2.855E-14) ubiquitin-like protein ligase binding 9 (2.855E-14) ubiquitin-like protein ligase binding 9 (2.855E-14) disordered domain specific binding 4 (1.142E-11) disordered domain specific binding 7 (2.903E-08) protein kinase binding 7 (2.903E-08) protein kinase binding 7 (2.903E-08) protein domain specific binding 7 (2.903E-08) protein domain specific binding 7 (2.903E-08) protein domain specific binding 9 (2.903E-08) protein binding 9 (2.903E-08) protein binding 9 (2.903E-08) protein phosphatase binding 9 (2.903E-08) protein phosphatase binding 9 (2.903E-08) protein phosphatase binding 9 (2.903E-08) protein phosphatase binding 9 (2.902E-08) Phosphatase Phosphatase Phosphatase Phosphatase Phospha		proteas mediated ubiquitin-dependent protein catabolic process	6	1 243E-07	
GO CC elsubstrate binding for the set of the		regulation of mitatic coll cyclo phase transition	6	1 484E 07	
GC CC MF equation of cells (2x10 mprohogenesis) 5 1.782E-07 dividually in protein ligase binding 9 2.855E-14 ubiquitin-like protein ligase binding 9 5.039E-14 intric-oxide synthase regulator activity 4 1.142E-11 disordered domain specific binding 8 4.315E-09 protein domain specific binding 7 5.903E-08 protein domain specific binding 7 5.903E-08 protein domain specific binding 8 4.315E-09 protein domain specific binding 7 5.903E-08 Protease binding 7 1.313E-06 integrin binding 9 4.1015E-06 cell adhesion molecule binding 3 4.102E-05 integrin binding 3 8.104E-05 protein binding 9 3 8.104E-05 protein phosphatase binding 4 8.325E-05 protein phosphatase binding 4 8.325E-05 pigment granule 1000 protein phosphatase 1000 protein phos		regulation of nilloud cell cycle phase transition	0	1.4040-07	
GO MF ubiquitin protein ligase binding GO MF ubiquitin-like protein ligase binding Intric-oxide synthase regulator activity Intric-oxide synthase synthase Intrin-Intric		regulation of cell cycle G2/M phase transition	5	1.558E-07	
GO MFUbiquitin protein ligase binding92.285E-14ubiquitin jorden ligase binding95.039E-14nitric-oxide synthase regulator activity41.142E-11disordered domain specific binding84.315E-09protein kinase binding75.903E-08protein domain specific binding78.076E-08Protease binding61.313E-05protein domain specific binding34.105E-06cell adhesion molecule binding34.105E-06unfolded protein binding34.102E-05integrin binding38.104E-05protein phosphatase binding39.162E-05integrin binding39.162E-05protein phosphatase binding30.0002008chromatin binding30.0002008chromatin binding33.392E-05protein phosphatase binding33.392E-05protein phosphatase binding33.392E-05protein phosphatase binding33.392E-05protein phosphatase binding33.392E-05pigment granule lumen33.392E-05pigment granule lumen35.163E-05pigment granule lumen55.163E-05ficolin-1-rich granule lumen40.000151growth cone30.000174perincelar region of the cytoplasm55.621E-05ficolin-1-rich granule30.0001782perincelar digrowth30.0001582perincelar digrowth3	00.L/F	developmental growth involved in morphogenesis	5	1.782E-07	
digutin-like protein ligase binding95.038E-14ntitic-oxide synthase regulator activity41.142E 11disordered domain specific binding84.315E-09protein kinase binding75.903E-08protein domain specific binding78.076E-08Protease binding78.076E-08protein domain specific binding34.1015E-06cell adhesion molecule binding34.105E-05histone deacet/jase binding34.105E-05unfolded protein binding39.162E-05protein hinding99.162E-05protein phosphatase binding30.0002008chromatin binding30.0002008chromatin binding33.392E-05protein phosphatase binding33.392E-05protein phosphatase binding33.392E-05protein phosphatase binding33.392E-05protein phosphatase binding33.392E-05protein phosphatase binding33.392E-05protein phosphatase binding33.392E-05pigment granule33.14E-05secretory granule luman35.416E-05chromatin protein-containing complex55.621E-05intracellular protein-containing complex40.0001561growth cone30.0001772neuronal cell body30.0001772site of polarized growth30.0001772protein-DNA complex30.0001772protein-DNA complex	GO MF	ubiquitin protein ligase binding	9	2.855E-14	
nitric-oxide synthase regulator activity41.142E-11disordered domain specific binding44.166E-09Kinase binding75.903E-08protein kinase binding78.076E-08Protease binding41.015E-06Cell adhesion molecule binding51.313E-05histone deacetylase binding34.106E-05unfolded protein binding38.104E-05protein binding38.104E-05protein binding30.0002008unfolded protein binding30.0002008protein phosphatase binding33.382E-05protein phosphatase binding33.382E-05protein phosphatase binding33.382E-05protein phosphatase binding33.382E-05protein phosphatase binding33.382E-05protein phosphatase binding33.382E-05pigment granule33.725E-05pigment granule lumen55.163E-05otypipasmic vesicle lumen55.163E-05intracellular protein-containing complex55.621E-05focal adhesion40.000151growth cone30.0001585neuronal cell body40.0001585site of polarized growth30.0001772protein-DNA complex30.0001772		ubiquitin-like protein ligase binding	9	5.039E-14	
disordered domain specific binding 8 4.166E-09 protein kinase binding 7 5.03E-08 protein kinase binding 7 8.076E-08 protein domain specific binding 7 8.076E-08 Protease binding 4 1.015E-06 cell adhesion molecule binding 3 4.105E-05 histone deacetylase binding 3 4.912E-05 integrin binding 3 9.162E-05 protein phosphatase binding 3 9.162E-05 protein phosphatase binding 3 0.0002986 chromatin binding 3 0.0002986 chromatin binding 3 0.0002986 chromatin binding 3 0.0002986 protein phosphatase binding 3 0.0002986 chromatin binding 3 0.392E-05 protein phosphatase binding 3 0.392E-05 protein phosphatase binding 3 0.392E-05 protein phosphatase binding 3 0.392E-05 pigment granule secretory granule lumen 4 0.55E-05 fcolin-1-rich granule lumen 5 1.147E-06 intracellular protein-containing complex 5 5.621E-05 focal adhesion 4 9.86E-05 cell-substrate junction growth cone 4 9.86E-05 cell-substrate junction growth cone 4 0.0001582 neuronal cell body neuronal cell body neuronal cell body protein-DNA complex 6 0.0001772 protein-DNA complex 7 0.0001744 fcolin-1-rich granule		nitric-oxide synthase regulator activity	4	1.142E-11	
Kinase binding84.315E-09protein kinase binding75.903E-08protein domain specific binding41.015E-06cell adhesion molecule binding51.313E-05histone deacetylase binding34.105E-06unfolded protein binding34.105E-06integrin binding39.102E-05integrin binding39.102E-05protein phosphatase binding30.0002008protein phosphatase binding30.0002008chromatin binding40.0002956protein phosphatase binding33.392E-05protein granule33.392E-05pigment granule33.392E-05percinculear region of the cytoplasm43.75EE-05percinculear region of the cytoplasm55.163E-05ficolin-1-rich granule lumen35.416E-05intracellular protein-containing complex55.621E-05focal adhesion40.000151growth cone30.0001782neuronal cell body40.0001582neuronal cell body30.0001774ifcolin-1-rich granule30.0001774growth cone30.0001774ifcolin-1-rich granule30.0001772protein-DNA complex30.0002502		disordered domain specific binding	4	4.166E-09	
protein kinase binding75.903E-08protein domain specific binding78.076E-08Protease binding1.015E-06cell adhesion molecule binding51.313E-05histone deacetylase binding34.912E-05integrin binding39.162E-05protein binding39.162E-05protein protein binding39.162E-05protein phosphatase binding39.162E-05protein phosphatase binding39.162E-05protein phosphatase binding30.0002296protein phosphatase binding33.332E-05protein phosphatase binding33.332E-05pigment granule33.332E-05pigment granule33.332E-05potoplasmic vesicle lumen43.55E-05potoplasmic vesicle lumen55.163E-05fociln-1-rich granule lumen55.163E-05fociln-1-rich granule lumen49.86E-05fociln-1-rich granule lumen40.0001581gerwth cone30.0001582neuronal cell body40.0001582neuronal cell body30.0001744fociln-1-rich granule30.0001744fociln-1-rich granule30.0001772protein-DNA complex30.0001772		Kinase binding	8	4.315E-09	
protein domain specific binding 7 8.076E-08 Protease binding 4 1.015E-06 cell adhesion molecule binding 5 1.313E-05 histone deacetylase binding 3 4.105E-05 unfolded protein binding 3 4.912E-05 integrin binding 3 9.162E-05 protein phosphatase binding 3 0.0002008 chromatin binding 4 0.0002086 chromatin binding 3 3.392E-05 melanosome 3 3.392E-05 pigment granule 3 3.392E-05 secretory granule lumen 4 3.55E-05 perinuclear region of the cytoplasm 5 5.163E-05 ficolin-1-rich granule lumen 5 5.163E-05 intracellular protein-containing complex 5 5.621E-05 focal adhesion 4 0.0001581 growth cone 3 0.0001582 neuronal cell body 4 0.0001585 iste of polarized growth 3 0.00001744 ficolin-1-rich granule<		protein kinase binding	7	5.903E-08	
Protease binding41.015E-06cell adhesion molecule binding51.313E-05histone deacetylase binding34.012E-05unfolded protein binding34.912E-05integrin binding39.162E-05protein phosphatase binding39.162E-05protein phosphatase binding30.0002098chromatin binding40.0002956veside lumen51.147E-06melanosome33.392E-05protein yosphatase binding33.392E-05pigment granule33.392E-05perinuclear region of the cytoplasm55.163E-05picolin-1-rich granule lumen35.416E-05intracellular protein-containing complex49.86E-05coll-substrate junction49.86E-05coll-substrate junction40.0001582neuronal cell body40.0001585site of polarized growth30.0001724ficolin-1-rich granule30.0001774ficolin-1-rich granule30.0001774site of polarized growth30.0001774ficolin-1-rich granule30.0001774protein-DNA complex30.0002502		protein domain specific binding	7	8.076E-08	
cell adhesion molecule binding51.313E-05histone deacetylase binding34.105E-05unfolded protein binding34.912E-05protein phosphatase binding39.162E-05Phosphatase binding30.0002086chromatin binding40.0002956GO CCvesicle lumen51.147E-06melanosome33.392E-05pigment granule33.392E-05perinuclear region of the cytoplasm55.163E-05cytoplasmic vesicle lumen33.725E-05perinuclear region of the cytoplasm55.163E-05focal adhesion49.86E-05cell-substrate junction49.86E-05cell-substrate junction40.0001051growth cone30.0001585site of polarized growth30.0001784focin-1-rich granule30.0001772protein-DNA complex30.0001772		Protease binding	4	1.015E-06	
histone deacetylase binding histone deacetylase binding unfolded protein binding integrin binding protein phosphatase binding Phosphatase binding chromatin binding downamic binding chromatin binding GO CC vesicle lumen melanosome pigment granule secretory granule lumen vesicle lumen secretory granule lumen vesicle lumen prinuclear region of the cytoplasm intracellular protein-containing complex focal adhesion cell-substrate junction growth cone neuronal cell body site of polarized growth focolin-1-rich granule are containing protein-DNA complex downamic protein-DNA complex downamic protein-DNA complex downamic protein-DNA complex downamic protein-DNA complex downamic protein-DNA complex downamic protein-DNA complex protein-DNA complex downamic protein-DNA complex protein-DNA		cell adhesion molecule binding	5	1.313E-05	
Institute for dealed yease binding34.102-00unfolded protein binding34.912E-05integrin binding39.162E-05protein phosphatase binding30.0002008chromatin binding40.0002956GO CCvesicle lumen51.147E-06melanosome33.392E-05pigment granule33.392E-05secretory granule lumen43.55E-05cytoplasmic vesicle lumen43.55E-05ficolin-1-rich granule35.416E-05intracellular protein-containing complex55.621E-05focal achesion49.86E-05cell-substrate junction30.0001582neuronal cell body40.0001585site of polarized growth30.0001744ficolin-1-rich granule30.0001772protein-DNA complex30.0001772		histono doscatulase hinding	3	1.010E-00	
uninoided protein binding 3 4.912E-05 integrin binding 3 9.162E-05 protein phosphatase binding 3 0.0002008 chromatin binding 4 0.0002956 chromatin binding 5 1.147E-06 melanosome 3 3.392E-05 pigment granule 3 3.392E-05 secretory granule lumen 4 3.55E-05 cytoplasmic vesicle lumen 4 3.52E-05 ficolin-1-rich granule lumen 5 5.163E-05 ficolin-1-rich granule lumen 5 5.621E-05 intracellular protein-containing complex 5 5.621E-05 focal adhesion 4 9.86E-05 cell-substrate junction 3 0.0001582 neuronal cell body 4 0.0001582 site of polarized growth 3 0.0001585 site of polarized growth 3 0.0001772 protein-DNA complex 3 0.0001772		historie deadelylase birlaing	0	4.1052-05	
integran binding38.104E-05protein phosphatase binding30.0002008Chromatin binding40.0002956chromatin binding51.147E-06melanosome33.392E-05pigment granule33.392E-05secretory granule lumen43.725E-05oytoplasmic vesicle lumen43.725E-05perinuclear region of the cytoplasm55.163E-05ficolin-1-rich granule lumen35.416E-05intracellular protein-containing complex55.621E-05focal adhesion40.0001051growth cone30.0001582neuronal cell body40.0001585site of polarized growth30.0001772protein-DNA complex30.0001772		unfolded protein binding	3	4.912E-05	
protein phosphatase binding39.162E-05Phosphatase binding30.0002096chromatin binding40.0002956GO CCvesicle lumen51.147E-06melanosome33.392E-05pigment granule33.392E-05secretory granule lumen43.55E-05cytoplasmic vesicle lumen43.725E-05perinuclear region of the cytoplasm55.163E-05ficolin-1-rich granule lumen35.416E-05intracellular protein-containing complex55.621E-05focal adhesion49.86E-05cell-substrate junction30.0001582neuronal cell body40.0001585site of polarized growth30.0001744ficolin-1-rich granule30.0001772protein-DNA complex30.0001772		integrin binding	3	8.104E-05	
Phosphatase binding30.0002008chromatin binding40.0002956GO CCvesicle lumen51.147E-06melanosome33.392E-05pigment granule33.392E-05secretory granule lumen43.55E-05cytoplasmic vesicle lumen43.725E-05perinuclear region of the cytoplasm55.163E-05ficolin-1-rich granule lumen35.416E-05focal adhesion49.86E-05cell-substrate junction40.0001581growth cone30.0001582neuronal cell body40.0001585site of polarized growth30.0001774ficolin-1-rich granule30.0001772pertein-DNA complex30.000208		protein phosphatase binding	3	9.162E-05	
chromatin binding40.0002956GO CCvesicle lumen51.147E-06melanosome33.392E-05pigment granule33.392E-05secretory granule lumen43.725E-05cytoplasmic vesicle lumen43.725E-05perinuclear region of the cytoplasm55.163E-05ficolin-1-rich granule lumen35.410E-05intracellular protein-containing complex55.621E-05focal adhesion40.0001051growth cone30.0001582neuronal cell body40.0001585site of polarized growth30.0001774ficolin-1-rich granule30.0001772pienule complex50.0002502		Phosphatase binding	3	0.0002008	
GO CCvesicle lumen51.147E-06melanosome33.392E-05pigment granule33.392E-05secretory granule lumen43.55E-05cytoplasmic vesicle lumen43.725E-05perinuclear region of the cytoplasm55.163E-05ficolin-1-rich granule lumen35.416E-05intracellular protein-containing complex55.621E-05focal adhesion49.86E-05growth cone30.0001051growth cone30.0001582neuronal cell body40.0001585site of polarized growth30.0001774ficolin-1-rich granule30.0001772protein-DNA complex30.0002502		chromatin binding	4	0.0002956	
melanosome33.392E-05pigment granule33.392E-05secretory granule lumen43.55E-05cytoplasmic vesicle lumen43.725E-05perinuclear region of the cytoplasm55.163E-05ficolin-1-rich granule lumen35.416E-05intracellular protein-containing complex55.621E-05focal achesion49.86E-05cell-substrate junction30.0001051growth cone30.0001582neuronal cell body40.0001585site of polarized growth30.0001744ficolin-1-rich granule30.0001772protein-DNA complex30.0002502	GO CC	vesicle lumen	5	1.147E-06	
pigment granule33.392E-05secretory granule lumen43.55E-05cytoplasmic vesicle lumen43.725E-05perinuclear region of the cytoplasm55.163E-05ficolin-1-rich granule lumen35.416E-05intracellular protein-containing complex55.621E-05focal adhesion49.86E-05cell-substrate junction30.0001582neuronal cell body40.0001585site of polarized growth30.0001744ficolin-1-rich granule30.0001772protein-DNA complex30.0002502		melanosome	3	3.392E-05	
secretory granule lumen secretory granule lumen cytoplasmic vesicle lumen ficolin-1-rich granule lumen intracellular protein-containing complex focal adhesion cell-substrate junction growth cone neuronal cell body site of polarized growth ficolin-1-rich granule protein-DNA complex 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3		piament granule	3	3.392E-05	
cytoplasmic vesicle lumen43.725E-05perinuclear region of the cytoplasm55.163E-05ficolin-1-rich granule lumen35.416E-05intracellular protein-containing complex55.621E-05focal adhesion49.86E-05cell-substrate junction40.0001051growth cone30.0001582neuronal cell body40.0001885site of polarized growth30.0001744ficolin-1-rich granule30.0001772protein-DNA complex30.0002502		secretory granule lumen	4	3.55E-05	
being basis45.121-03perinuclear region of the cytoplasm55.163E-05ficolin-1-rich granule lumen35.416E-05intracellular protein-containing complex55.621E-05focal adhesion49.86E-05cell-substrate junction40.0001051growth cone30.0001582neuronal cell body40.0001585site of polarized growth30.0001774ficolin-1-rich granule30.0001772protein-DNA complex30.0002502			4	2 725E 05	
perinductar region of the cytoplasm55.163E-05ficolin-1-rich granule lumen35.416E-05intracellular protein-containing complex55.621E-05focal adhesion49.86E-05cell-substrate junction40.0001051growth cone30.0001582neuronal cell body40.0001784site of polarized growth30.0001744ficolin-1-rich granule30.0001772protein-DNA complex30.0002502			4	5.7252-05	
Iteoin-1-rich granule lumen35.416E-05intracellular protein-containing complex55.621E-05focal adhesion49.86E-05cell-substrate junction40.0001051growth cone30.0001582neuronal cell body40.0001585site of polarized growth30.0001744ficolin-1-rich granule30.0001772protein-DNA complex30.0002502		pennuclear region of the cytoplasm	5	5.163E-05	
intracellular protein-containing complex55.621E-05focal adhesion49.86E-05cell-substrate junction40.0001051growth cone30.0001582neuronal cell body40.0001585site of polarized growth30.0001744ficolin-1-rich granule30.0001772protein-DNA complex30.0002502		ticolin-1-rich granule lumen	3	5.416E-05	
focal adhesion 4 9.86E-05 cell-substrate junction 4 0.0001051 growth cone 3 0.0001582 neuronal cell body 4 0.0001585 site of polarized growth 3 0.0001744 ficolin-1-rich granule 3 0.0001772 protein-DNA complex 3 0.0002502		intracellular protein-containing complex	5	5.621E-05	
cell-substrate junction 4 0.0001051 growth cone 3 0.0001582 neuronal cell body 4 0.0001885 site of polarized growth 3 0.0001744 ficolin-1-rich granule 3 0.0001772 protein-DNA complex 3 0.0002502		focal adhesion	4	9.86E-05	
growth cone 3 0.0001582 neuronal cell body 4 0.0001585 site of polarized growth 3 0.0001744 ficolin-1-rich granule 3 0.0001772 protein-DNA complex 3 0.0002502		cell-substrate junction	4	0.0001051	
neuronal cell body40.0001585site of polarized growth30.0001744ficolin-1-rich granule30.0001772protein-DNA complex30.0002502		growth cone	3	0.0001582	
site of polarized growth30.0001744ficolin-1-rich granule30.0001772protein-DNA complex30.0002502		neuronal cell body	4	0.0001585	
ficolin-1-rich granule 3 0.0001772 protein-DNA complex 3 0.0002502		site of polarized growth	3	0.0001744	
protein-DNA complex 3 0.0002502		ficolin-1-rich granule	3	0.0001772	
		protein-DNA complex	с С	0.0001772	
			0	0.0002002	

series of critical physiological activities. Nevertheless, only the phosphorylation of PI3K and Akt mainly participate in these physiological activities. Besides, growing numbers of studies

have found that cell apoptosis is closely related to the PI3K/Akt pathway (Xue and Feng, 2018; Zhan and Yan, 2020). Therefore, we evaluated the effect of BTP on the PI3K/Akt pathway in osteoclasts.



FIGURE 4 | Functional enrichment of the core targets of BTP-DEGs. (A) GO enrichment. (B) KEGG enrichment. (C) Network of Key Targets-Pathway. (D) Pathway map of key targets.



In the present study, both immunofluorescence and western blot assays were performed to determine the effect of BTP on the PI3K/ Akt signaling pathway in osteoclasts. The results revealed that after pretreatment with BTP, the expression of p-Akt and p-PI3K was reduced, while no noticeable change was evident in the expression of AKT and PI3K compared to the control group (**Figure 8B**). Likewise, as presented in **Figure 8C**, the result of the immunofluorescence revealed that green fluorescence becomes



weaker, indicating that the expression of p-Akt was reduced, and the red fluorescence (the expression of Akt) had no apparent change.

DISCUSSION

It is widely known that TCM has shown broad application prospects in treating various intractable diseases and has become increasingly recognized globally (Zhang et al., 2021; Long et al., 2020). TCM also provides abundant resources for the development of new drugs. However, it remains a challenge to study the mechanisms of action of the TCM formula due to their characteristic of multicomponents, multitargets, and multipathways (Yu and Qi, 2020). Network pharmacology, first put forward by Hopkins in 2007, can analyze the connection of components, targets, and diseases in the network systematically and study the multilayer and multipathway mechanism of action of medications comprehensively, which coincides with the fundamental concept of holism in TCM (Hopkins, 2007; Sheng et al., 2020). Thus, it has become increasingly indispensable for performing qualified basic research of TCM formulas (Zhang et al., 2021). In addition, network pharmacology may realize "drug relocation" and explore new biological activities of drugs, thus expanding the application scope. As a result, it has been widely used in pharmacological research regarding TCM.

BTP has a long history of clinical applications for ONFH treatment and is composed of *Angelica sinensis* (Oliv.) Diels, *Pheretima aspergillum* (E.Perrier), *Panax notoginseng* (Burk.) F. H. Chen, *Astragalus membranaceus* (Fisch.) Bge, and *Glycyrrhiza uralensis* Fisch. This TCM formula has the effects of nourishing





400), p-Akt (green) and Akt (red).

blood, promoting blood circulation, dredging collaterals, and relieving pain. Although the anti-ONFH effect of BTP has been well documented, its active components and mechanisms of action remain obscure and need further research. In this study, a total of 34 compounds were identified. Among these, six compounds (caffeic acid, pimpinellin, Z-ligustilide, ferulic acid, chlorogenic acid, and benzoic acid) belonged to Angelica sinensis (Oliv.) Diels, seven (ononin, biochanin a, formononetin, sucrose, calycosin-7-O-β-Dglucoside, asparagine, and daidzein) to Astragalus membranaceus (Fisch.)Bge, six (liquiritin, isoliquiritigenin, isoliquiritin, glycyrrhizic acid, licochalcone A, and licoricesaponin g2) to Glycyrrhiza uralensis Fisch., eight (caffeic acid, 3-coumaric acid, psoralen, gypenoside xvii, ginsenoside Rb1, and ginsenoside re) to Panax notoginseng (Burk.), and nine (succinic acid, hypoxanthine, DL-arginine, nicotinic acid, guanine, guanosine, phenylalanine, tryptophan, and inosine) to Pheretima aspergillum (E. Perrier). Formononetin and daidzein have been reported to inhibit RANKL-induced osteoclast differentiation and regulate osteogenic differentiation, indicating that they may become potential drugs for preventing and treating bone destruction in ONFH. In addition, another study has shown that the extract of Panax notoginseng (Burk.) could significantly promote the repair of the femoral head in rabbits with ONFH and improve the bone density and bone microstructure (Gui et al., 2019), which was also supported by clinical research (Jia et al., 2011).

KEGG is one of the most used tools to predict the possible molecular mechanisms of drugs, particularly herbal medicines. In our present study, the KEGG enrichment of the core target genes revealed that these genes were significantly enriched in the PI3K-AKT signaling pathway and cell cycle. Numerous studies have confirmed that cell apoptosis is often accompanied by growth arrest, suggesting that cell cycle arrest correlates with apoptosis closely (Duan et al., 2021; Zhang et al., 2021). When CAF and theobromine, which can shorten the G2/M block time, were added before the exposure, the ratio of the G2/M phase decreased with more noticeable increases in apoptosis. In contrast, when TPA, IBMX, and 3-aminoben extending the G2/M block time were added, the G2/M ratio increased, while the apoptosis ratio decreased (Zhao et al., 1999). Shinomiya et al. used CAF to reduce the G2 blockade of mouse lymphoma cells EL-4 caused by cis-diamminedichloroplatinum and promote the occurrence of apoptosis (Shinomiya et al., 1997). As a result, we designed a series of in vitro experiments to verify our hypothesis. In the present study, CCK-8 results showed that BTP had no toxicity to RAW 264.7 cells under 150 µg/ml for 24 h treatment.

Therefore, we applied the concentration of 50, 75, and 100 µg/ml to the follow-up experiments. TRAP staining results showed that BTP at 75 and 100 µg/ml inhibited the formation of TRAP-positive multinucleated cells. In addition, the area of bone resorption *in vitro* was also significantly suppressed, illustrating that BTP could inhibit the formation of osteoclasts. In addition, the results of flow cytometry revealed that BTP could induce remarkable apoptosis in osteoclasts (RANKL-induced RAW 264.7 cells) and decrease the mitochondrial membrane potential (MMOP, $\Delta\Psi$). Consequently, we determined the apoptosis-related proteins of C-caspase-3, Bax, and Bcl-2, and found that BTP could upregulate the antiapoptosis protein of Bcl-2, which is

consistent with the flow cytometry and MMOP analysis. The PI3K-Akt signaling pathway is closely related to cell apoptosis and has been recognized as a potential target for regulating cell survival and apoptosis (Zhang et al., 2019). Therefore, we speculated that the treatment effects of BTP on ONFH might associate with PI3K/Akt-mediated apoptosis. In our bioinformatics analysis, the results indicated that the effects of BTP might be closely related to the PI3K/Akt signaling pathway, which is also an important upstream signaling for apoptosis. Therefore, we determined the expressions of PI3K/Akt signal-related proteins, including PI3K, phosphorylation (p)-PI3K, Akt, and p-Akt. Our results demonstrated that BTP treatment could downregulate the expressions of p-PI3K and p-Akt, subsequently resulting in cell apoptosis of osteoclasts (RANKL induced RAW 264.7 cells).

CONCLUSION

In conclusion, our present results suggested that BTP treatment could be beneficial for the osteonecrosis of the femoral head (ONFH), and the possible mechanisms are related to suppressing the formation of osteoclasts and induction of apoptosis in osteoclasts via regulation of the PI3K/Akt signaling pathway (Calder et al., 2004, Dhomen et al., 2012, Huang et al., 2004, Hua, 2017, Kimura et al., 2006, Lanaya et al., 2014, Linder et al., 2018, Lv et al., 2021, Mettey et al., 2003, Okuma et al., 2008, Poeta et al., 2007, Roovers et al., 2007, Ren et al., 2013, Savio et al., 2014, Schneider et al., 2009, Soussi, 2000, Xu et al., 2020, Yu et al., 2020, Zhang et al., 2014).

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: PRIDE (Proteomics Identification Database, https://www.ebi.ac.uk/pride/archive). The Project Name: Analysis of components of Buxuetongluo Pills by LC-MS/MS, Project accession: PXD027269.

AUTHOR CONTRIBUTIONS

All authors contributed to the article and approved the submitted version. YHC, QR, and XPT conceived and designed this paper. DW, YCL, DT completed the main experiment content. HL, RL processed all the pictures in the article. DW and YCL analyzed the data and wrote the original draft of the paper. YHC reviewed and edited the paper. Additionally, WS helped complete the test of osteogenic differentiation and bone resorption, and SJ helped complete all the confocal imaging.

FUNDING

This research was supported by the Sichuan Science and Technology Program (Grant No. 2020YFS0525), the

International Cooperation and Exchange Project of Sichuan Provincial Science and Technology Department (Grant No. 2017HH0004), the National Natural Science Foundation of China (Grant No. 81603537), the Sichuan Provincial

REFERENCES

- Calder, J. D., Buttery, L., Revell, P. A., Pearse, M., and Polak, J. M. (2004). Apoptosis--a Significant Cause of Bone Cell Death in Osteonecrosis of the Femoral Head. J. Bone Jt. Surg Br 86 (8), 1209–1213. doi:10.1302/0301-620x.86b8.14834
- Chen, L., Qi, J., Chang, Y. X., Zhu, D., and Yu, B. (2009). Identification and Determination of the Major Constituents in Traditional Chinese Medicinal Formula Danggui-Shaoyao-San by HPLC-DAD-ESI-MS/MS. J. Pharm. Biomed. Anal. 50 (2), 127–137. doi:10.1016/j.jpba.2009.03.039
- Clough, E., and Barrett, T. (2016). The Gene Expression Omnibus Database. Methods Mol. Biol. 1418, 93-110. doi:10.1007/978-1-4939-3578-9_5
- Cui, Y., Li, C., Zeng, C., Li, J., Zhu, Z., Chen, W., et al. (2018). Tongmai Yangxin Pills Anti-oxidative Stress Alleviates Cisplatin-Induced Cardiotoxicity: Network Pharmacology Analysis and Experimental Evidence. Biomed. Pharmacother. 108, 1081–1089. doi:10.1016/j.biopha.2018.09.095
- Daina, A., Michielin, O., and Zoete, V. (2019). SwissTargetPrediction: Updated Data and New Features for Efficient Prediction of Protein Targets of Small Molecules. *Nucleic Acids Res.* 47 (W1), W357–W364. doi:10.1093/nar/gkz382
- Dhomen, N. S., Mariadason, J., Tebbutt, N., and Scott, A. M. (2012). Therapeutic Targeting of the Epidermal Growth Factor Receptor in Human Cancer. *Crit. Rev. Oncog* 17 (1), 31–50. doi:10.1615/critrevoncog.v17.i1.40
- Duan, H., Zhang, Q., Liu, J., Li, R., Wang, D., Peng, W., et al. (2021). Suppression of Apoptosis in Vascular Endothelial Cell, the Promising Way for Natural Medicines to Treat Atherosclerosis. *Pharmacol. Res.* 168, 105599. doi:10.1016/j.phrs.2021.105599
- Gui, X., Jiang, Z., Chen, B., Yu, J., and Yang, Y. (2019). Effect of Radix et *Rhizoma Notoginseng* on the microstructure of femoral head in rabbits with steroidinduced osteonecrosis of femoral head and Its Mechanism. J. New Chin. Med. 51 (12), 9–12.
- Hopkins, A. L. (2007). Network Pharmacology. Nat. Biotechnol. 25(10), 1110–1111. doi: doi:10.1038/nbt1007-1110
- Hopkins, A. L. (2008). Network Pharmacology: The Next Paradigm in Drug Discovery. Nat. Chem. Biol. 4 (11), 682–690. doi:10.1038/nchembio.118
- Hua, Y. (2017). Expression of P53 Gene in the Blood of Patients with Alcohol-Induced Avascular Necrosis of the Femoral Head and its Mechanism on Osteoblast Apoptosis. *Anat. Res* 39 (02), 136–139.
- Huang, da. W., Sherman, B. T., and Lempicki, R. A. (2009). Bioinformatics Enrichment Tools: Paths toward the Comprehensive Functional Analysis of Large Gene Lists. *Nucleic Acids Res.* 37 (1), 1–13. doi:10.1093/nar/ gkn923
- Huang, Y., Luo, X., Guo, K., An, H., and Jiang, D. (2004). Effect of Endogenous Glucocorticoid on Expression of P53 and Bcl-2 Proteins in Osteocyte Apoptosis in Avascular Necrosis of the Femoral Head Induced by Alcoholism. *Guizhou. Med. J.* 12, 1059–1062.
- Jia, B., Fan, W., Chen, G., Li, Y., Zhang, G., Yang, Sh., et al. (2019). Development of UPLC-MS Combined with HPLC Technique to Explore the Effects of Exogenous Substances on the Saponin Contents and Growth of *Panax Notoginseng* Leaves. J. Yunnan Agric. Univ. 34 (01), 116–123. doi:10.12101/ j.issn.1004-390X(n).201712011
- Jia, F., Sun, R., Li, Y., Liu, B., Zhao, F., and Xiong, Y. (2011). Study on Prevention and Treatment of Femoral Head Necrosis after Femoral Neck Fracture with *Sanqi Danshen* Tablet. *Chin. J. Orthop. Traumatol.* 6, 12–14.
- Kimura, H., Fujiwara, Y., Sone, T., Kunitoh, H., Tamura, T., Kasahara, K., et al. (2006). EGFR Mutation Status in Tumour-Derived DNA from Pleural Effusion Fluid Is a Practical Basis for Predicting the Response to Gefitinib. *Br. J. Cancer* 95 (10), 1390–1395. doi:10.1038/sj.bjc.6603428
- Lanaya, H., Natarajan, A., Komposch, K., Li, L., Amberg, N., Chen, L., et al. (2014). EGFR Has a Tumour-Promoting Role in Liver Macrophages during Hepatocellular Carcinoma Formation. *Nat. Cel Biol.* 16 (10), 972–977. doi:10.1038/ncb3031

Administration of Traditional Chinese Medicine (Grant No. 2021MS464), and the Youth Scholarship of Chengdu University of Traditional Chinese Medicine (Grant No. QNXZ2019043).

- Linder, M., Hecking, M., Glitzner, E., Zwerina, K., Holcmann, M., Bakiri, L., et al. (2018). EGFR Controls Bone Development by Negatively Regulating mTOR-Signaling during Osteoblast Differentiation. *Cell Death Differ* 25 (6), 1094–1106. doi:10.1038/s41418-017-0054-7
- Liu, J., Wang, X., Cai, S., Katsuko, K., and Tsuneo, N. (2004). Analysis of the Constituents in the Chinese Drug Notoginseng by Liquid Chromatography-Electrospray Mass Spectrometry. *Chin. Pharm. J.* 13 (4). doi:10.1021/ja961604z
- Liu, L., Duan, J., and Tang, Y. (2017). Study on Chemical Component and Synergetic Effect of Concerted Application of Chinese Angelica and Safflower by Using UHPLC-Q-TOF-MS. *Chin. J. Tradit. Chin. Med. Pharm.* 3, 996–1000.
- Liu, M. H., Tong, X., Wang, J. X., Zou, W., Cao, H., and Su, W. W. (2013). Rapid Separation and Identification of Multiple Constituents in Traditional Chinese Medicine Formula Shenqi Fuzheng Injection by Ultra-fast Liquid Chromatography Combined with Quadrupole-Time-Of-Flight Mass Spectrometry. J. Pharm. Biomed. Anal. 74, 141–155. doi:10.1016/ j.jpba.2012.10.024
- Liu, M., Hui, O., Jia, J., Huang, W., Guo, S., He, M., et al. (2019). Analysis of Anticomplement Activity and Active Ingredients of *Gynura Procumbens* by UPLC-Q-TOF-MS. *Chin. Tradit Pat Med.* 41 (11), 2681–2687.
- Liu, Z., Jiang, M., Lu, X., Qin, F., Song, Y., Wen, J., et al. (2012). Simultaneous Determination of Pimpinellin, Isopimpinellin and Phellopterin in Rat Plasma by a Validated UPLC-MS/MS and its Application to a Pharmacokinetic Study after Administration of *Toddalia Asiatica* Extract. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 891-892, 102–108. doi:10.1016/j.jchromb.2012.02.022
- Luo, L., Gao, W., Zhang, Y., Liu, C., Wang, G., Wu, H., et al. (2020). Integrated Phytochemical Analysis Based on UPLC-MS and Network Pharmacology Approaches to Explore the Quality Control Markers for the Quality Assessment of *Trifolium Pratense* L. *Molecules* 25 (17), 3787. doi:10.3390/ molecules25173787
- Lv, W., Yu, M., Yang, Q., Kong, P., and Yan, B. (2021). Total Flavonoids of Rhizoma Drynariae Ameliorate Steroid-induced A-vascular N-ecrosis of the F-emoral H-ead via the PI3K/AKT P-athway. *Mol. Med. Rep.* 23 (5). doi:10.3892/mmr.2021.11984
- Meng, X., Li, H., Song, F., Liu, C., Liu, Z., and Liu, S. (2009). Studies on Triterpenoids and Flavones inGlycyrrhiza uralensisFisch. By HPLC-ESI-MSnand FT-ICR-MSn. *Chin. J. Chem.* 27 (2), 299–305. doi:10.1002/ cjoc.200990048
- Mettey, Y., Gompel, M., Thomas, V., Garnier, M., Leost, M., Ceballos-Picot, I., et al. (2003). Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects. J. Med. Chem. 46 (2), 222–236. doi:10.1021/jm020319p
- Okuma, C., Kaketa, T., Hikita, A., Matsuda, K., Nakamura, M., Nagase, Y., et al. (2008). Potential Involvement of P53 in Ischemia/reperfusion-Induced Osteonecrosis. J. Bone Miner Metab. 26 (6), 576–585. doi:10.1007/s00774-007-0849-6
- Ping, C. (2021). Clinical Observation on Non-traumatic Femoral Head Necrosis Treated by Operation Combined with Huangqi Shenggu Decoction. J. Tradit Chin. Med. 37 (03), 427–429.
- Poeta, M. L., Manola, J., Goldwasser, M. A., Forastiere, A., Benoit, N., Califano, J. A., et al. (2007). TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck. N. Engl. J. Med. 357 (25), 2552–2561. doi:10.1056/ NEJMoa073770
- Pouya, F., and Kerachian, M. A. (2015). Avascular Necrosis of the Femoral Head: Are Any Genes Involved?. Arch. Bone Jt. Surg. 3 (3), 149–155. doi:10.22038/ abjs.2015.4294
- Qing, Z., Xinyue, D., Ruolan, L., Jiayi, S., Jia, L., Wei, P., et al. (2021). Inducing Apoptosis and Suppressing Inflammatory Reactions in Synovial Fibroblasts Are Two Important Ways for Guizhi-Shaoyao-Zhimu Decoction against Rheumatoid Arthritis. J. Inflamm. Res. 14, 217–236. doi:10.2147/jir.s287242

- Ren, Y., Zhu, Z., Zhang, W., Zhang, Y., and Zhang, H. (2013). HPLC-MS/MS Determination of Puerarin and Daidzein in Puerarin Root. *Phys. Test. Chem Anal B* 49 (04), 464–467.
- Roovers, R. C., Laeremans, T., Huang, L., De Taeye, S., Verkleij, A. J., Revets, H., et al. (2007). Efficient Inhibition of EGFR Signaling and of Tumour Growth by Antagonistic Anti-EFGR Nanobodies. *Cancer Immunol. Immunother.* 56 (3), 303–317. doi:10.1007/s00262-006-0180-4
- Savio, A. L., da Silva, G. N., de Camargo, E. A., and Salvadori, D. M. (2014). Cell Cycle Kinetics, Apoptosis Rates, DNA Damage and TP53 Gene Expression in Bladder Cancer Cells Treated with Allyl Isothiocyanate (Mustard Essential Oil). *Mutat. Res.* 762, 40–46. doi:10.1016/j.mrfmmm.2014.02.006
- Schneider, M. R., Sibilia, M., and Erben, R. G. (2009). The EGFR Network in Bone Biology and Pathology. *Trends Endocrinol. Metab.* 20 (10), 517–524. doi:10.1016/j.tem.2009.06.008
- Shan, J., Yang, R., Zhang, X., Shen, C., Shen, C., Ji, J., et al. (2018). Network Pharmacological Study of Antitussive and Expectorant Effective of Jiegeng Decotion. *Chin. Tradit Herb Drugs* 49, 3501–3508.
- Sheng, S., Huang, Y., Yang, Z., Li, J., and Xu, F. (2020). Conventional Drugs in New Use: Recognition on Pharmacological Effects of Tanshinone IIA Based on Gene Expression Profile and Connectivity Map. *Chin. J. Integr. Med. Cardio-/ cerebrovascuiar Dis.* 18 (18), 2967–2973.
- Shinomiya, N., Takemura, T., Iwamoto, K., and Rokutanda, M. (1997). Caffeine Induces S-phase Apoptosis in Cis-Diamminedichloroplatinum-Treated Cells, whereas Cis-Diamminedichloroplatinum Induces a Block in G2/M. Cytometry 27 (4), 365–373. doi:10.1002/(sici)1097-0320(19970401)27:4<365:aid-cyto8>3.0.co;2-b
- Soussi, T. (2000). The P53 Tumor Suppressor Gene: from Molecular Biology to Clinical Investigation. *Ann. N. Y Acad. Sci.* 910, 121–129. doi:10.1111/j.1749-6632.2000.tb06705.x
- Sun, B., and Li, G. (2013). Observation on 38 Cases of Femoral Head Necrosis Treated with Bushen Huoxue Decoction. J. Tradit Chin. Med. 29 (12), 987–988.
- Wang, S., Tong, Y., Yang, Y., and Shi, Y. (2020). Mechanism of Wuling Powder in Treatment of Diabetic Kidney Disease Based on Network Pharmacology. World Chin. Med. 15 (22), 3383–3390. doi:10.3969/j.issn.1673-7202.2020.22.004
- Wu, H., Zhong, S., Peng, L., Wu, W., Li, Z., and Li, W. (2020). HPLC-ESI-MS/MS Analysis of Active Component Differences in astragalus before and after Honey-Fried. J. Chin. Mass. Spectr. Soc. 41 (06), 117–127. doi:10.7538/zpxb.2019.0121
- Xia, W., Hu, S., Wang, M., Xu, F., Han, L., and Peng, D. (2021). Exploration of the Potential Mechanism of the *Tao Hong Si Wu* Decoction for the Treatment of Postpartum Blood Stasis Based on Network Pharmacology and *In Vivo* Experimental Verification. *J. Ethnopharmacol.* 268, 113641. doi:10.1016/j.jep.2020.113641
- Xu, H., Chen, S., Zhang, H., Zou, Y., Zhao, J., Yu, J., et al. (2020). Network-based Analysis Reveals Novel Gene Signatures in the Peripheral Blood of Patients with Sporadic Nonsyndromic Thoracic Aortic Aneurysm. J. Cel Physiol 235 (3), 2478–2491. doi:10.1002/jcp.29152
- Xu, Q., Guo, Q., Wang, C. X., Zhang, S., Wen, C. B., Sun, T., et al. (2021). Network Differentiation: a Computational Method of Pathogenesis Diagnosis in Traditional Chinese Medicine Based on Systems Science. *Artif. Intell. Med.* 118():102134, doi:10.1016/j.artmed.2021.102134
- Xu, Q., Wang, X., Zhong, N., Wang, Y., Li, Z., and Cai, Y. (2021). A Network Pharmacology and Molecular Docking Study on Treatment Mechanism of Bacterial Dysentery of *Huanglian-Huangqin-Huangbo* Herb Pair. doi: doi:10.21203/rs.3.rs-147874/v1
- Xue, X. H., Feng, Z. H., Li, Z. X., and Pan, X. Y. (2018). Salidroside Inhibits Steroid-Induced Avascular Necrosis of the Femoral Head via the PI3K/Akt Signaling Pathway: *In Vitro* and *In Vivo* Studies. *Mol. Med. Rep.* 17 (3), 3751–3757. doi:10.3892/mmr.2017.8349
- Yan, Z., Zhan, J., Qi, W., Lin, J., Huang, Y., Xue, X., et al. (2020). The Protective Effect of Luteolin in Glucocorticoid-Induced Osteonecrosis of the Femoral Head. *Front. Pharmacol.* 11, 1195. doi:10.3389/fphar.2020.01195
- Yang, W., Feng, C., Kong, D., Shi, X., Cui, Y., Liu, M., et al. (2010). Simultaneous and Sensitive Determination of Xanthotoxin, Psoralen, Isoimpinellin and Bergapten in Rat Plasma by Liquid Chromatography-Electrospray Ionization Mass Spectrometry. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 878 (5-6), 575–582. doi:10.1016/j.jchromb.2009.12.035
- Yu, L., Qiyue, Y., Yan, X., Yulu, Z., Jinyan, W., Songyu, L., et al. (2020). Nose to Brain Drug Delivery - a Promising Strategy for Active Components from Herbal Medicine for Treating Cerebral Ischemia Reperfusion. *Pharmacol. Res.* 159, 104795. doi:10.1016/j.phrs.2020.104795

- Zhan, J., Yan, Z., Zhao, M., Qi, W., Lin, J., Lin, Z., et al. (2020). Allicin Inhibits Osteoblast Apoptosis and Steroid-Induced Necrosis of Femoral Head Progression by Activating the PI3K/AKT Pathway. *Food Funct.* 11, 7830–7841. doi:10.1039/D0FO00837K
- Zhang, J.-Z., Gao, W.-Y., Gao, Y., Liu, D., Liu, D.-L., and Huang, L.-Q. (2011). Analysis of Influences of Spaceflight on Chemical Constituents in Licorice by HPLC-ESI-MS/MS. Acta Physiol. Plant 33, 2511–2520. doi:10.1007/s11738-011-0796-7
- Zhang, Q., Duan, H. X., Li, R. L., Sun, J. Y., Liu, J., Peng, W., et al. (2021). Inducing Apoptosis and Suppressing Inflammatory Reactions in Synovial Fibroblasts Are Two Important Ways for Guizhi-Shaoyao-Zhimu Decoction against Rheumatoid Arthritis. J. Inflamm. Res. 14, 217–236. doi:10.2147/JIR.S287242
- Zhang, Q., Liu, J., Duan, H., Li, R., Peng, W., and Wu, C. (2021). Activation of Nrf2/ HO-1 Signaling: An Important Molecular Mechanism of Herbal Medicine in the Treatment of Atherosclerosis via the protection of Vascular Endothelial Cells from Oxidative Stress. J. Adv. Res. doi:10.1016/j.jare.2021.06.023
- Zhang, Q., Liu, J., Zhang, M., Wei, S., Li, R., Gao, Y., et al. (2019). Apoptosis Induction of Fibroblast-like Synoviocytes Is an Important Molecular-Mechanism for Herbal Medicine along with its Active Components in Treating Rheumatoid Arthritis. *Biomolecules* 9, 795. doi:10.3390/biom9120795
- Zhang, X., Qi, L. W., Yi, L., Li, P., Wen, X. D., and Yu, Q. T. (2008). Screening and Identification of Potential Bioactive Components in a Combined Prescription of Danggui Buxue Decoction Using Cell Extraction Coupled with High Performance Liquid Chromatography. *Biomed. Chromatogr.* 22 (2), 157–163. doi:10.1002/bmc.910
- Zhang, X., Zhu, J., Liu, F., Li, Y., Chandra, A., Levin, L. S., et al. (2014). Reduced EGFR Signaling Enhances Cartilage Destruction in a Mouse Osteoarthritis Model. *Bone. Res.* 2, 14015. doi:10.1038/boneres.2014.15
- Zhang, Y., Long, Y., Yu, S., Li, D., Yang, M., Guan, Y., et al. (2021). Natural Volatile Oils Derived from Herbal Medicines: A Promising Therapy Way for Treating Depressive Disorder. *Pharmacol. Res.* 164, 105376. doi:10.1016/ j.phrs.2020.105376
- Zhang, Y., Wei, W., Huo, J., and Wang, W. (2017). Serum Pharmacochemistry Study of *Pheretima Aspergillum* by UPLC-Q-TOF-MS. J. Chin. Med. Mat. 40 (004), 848–853.
- Zhao, H. (2020). Clinical Observation on 47 Cases of Early Non-traumatic Femoral Head Necrosis Treated by Taohong Siwu Decoction Combined with Acupuncture. *Chin. J. Ethn. Ethn.* 29 (14), 99–101.
- Zhao, W., Shou, H., and Chen, J. (1999). G2-M Phase Block and Tumor. Foreign Med. Sci. 2, 13–15.
- Zhao, Y., Liu, S., Zhang, C., Liu, D., and Zhang, T. (2016). Analysis on chemical constituents from *Glycyrrhizae Radix* et Rhizoma by HPLC-Q-TOF-M. *Chin. Med. Mat* 47 (12), 2061–2068. doi:10.7501/j.issn.0253-2670.2016.12.007
- Zheng, H., Yang, E., Peng, H., Li, J., Chen, S., Zhou, J., et al. (2014). Gastrodin Prevents Steroid-Induced Osteonecrosis of the Femoral Head in Rats by Antiapoptosis. *Chin. Med. J. (Engl)* 127 (22), 3926–3931. doi:10.3760/ cma.j.issn.0366-6999.20141371
- Zhou, Y., Zhou, B., Pache, L., Chang, M., Chanda, S. K., Khodabakhshi, A. H., et al. (2019). Metascape Provides a Biologist-Oriented Resource for the Analysis of Systems-Level Datasets. *Nat. Commun.* 10 (1), 1523. doi:10.1038/s41467-019-09234-6

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wang, Liu, Tang, Wei, Sun, Ruan, He, Li, Ren, Tian and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.